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Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity found in people 
with cystic fibrosis (pwCF). CFRD is associated with increased adverse outcomes and burden 
of treatment in pwCF as well as reduced quality of life. People with CFRD (pwCFRD) must 
measure their blood glucose levels several times per day to monitor their diabetes and so 
that treatment can be tailored to individuals. 
 
Continuous glucose monitoring systems (CGMS) are a relatively new technology that have 
been shown to be useful in diagnosing CFRD, but the impact of CGM on the monitoring and 
subsequent management of CFRD remains undetermined. This application of CGM has 
previously been approved in people with other forms of diabetes. 
 
Method 
For this work, engagement with stakeholders was undertaken to devise outcomes of 
interest that would make a meaningful impact on the lives and wellbeing of pwCFRD and 
those involved with their care. A protocol for an original Cochrane systematic review on 
the impact of CGM on pwCFRD was then created and the review itself was conducted. 
This included performing a comprehensive search of five major databases and assessing 
the eligibility of the results for inclusion in the study. A suggested framework for future 
research in this area was then created. 
Results 
Out of a total of 1768 studies, once duplicates were eliminated, there were found to be no 
completed RCT studies that appropriately fitted the protocol’s criteria for inclusion in the 
review. The only study that did meet the criteria was a single RCT protocol registered at 
clinicaltrials.gov (NCT03939065) which had not yet been undertaken, and thus, presented no 
data to be analysed for the review at this time. However, once this trial is completed, it may 
be eligible for inclusion in an update of this review. 
 
Discussion 
There is currently no evidence to support the costly implementation of CGM to manage 
CFRD, although there are indications that CGMS are already being used in this context.  
[6] 
 
CFRD is becoming more prevalent because of a range of factors including the improved life 
expectancy of pwCF. The impact of CFRD on peoples’ lives is of ever-growing importance and 
so it is now more pressing than ever to conduct research into ways to help alleviate both the 
treatment and disease burden for pwCFRD.  Ensuring new technologies are properly 
evaluated will contribute to the provision of a growing and robust body of evidence which in 
turn will support the decision-making of policy makers, clinicians, and patients alike. As 
discussed, there is currently no data available on the impact of CGM on the management of 
pwCFRD. However, it is noted that the absence of evidence is not evidence of absence of 
effect. It is hoped that publication of this review will raise the profile of the question at hand 
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Aims of this work 
 
• Engage with stakeholders to identify which outcome measures are most important to people 
with cystic fibrosis related diabetes. 
 
• Formulate, for publication, a protocol for an original Cochrane systematic review; 
‘Continuous glucose monitoring systems for people with cystic fibrosis related diabetes.’ 
 
• Perform and produce a Cochrane review for publication from said protocol. 
 
• Establish a framework for future trials to improve the evidence base on the impact of CGM 




























In preparation for this year of study, I spent time with the cystic fibrosis (CF) team at Alder 
Hey Children’s Hospital in Liverpool. I attended several CF clinics and had the opportunity to 
engage with young people with CF, and their families, to understand more about their 
experiences. This enabled me to identify that CF related diabetes presented considerable 
difficulties for a small, but significant, number of them. During these clinics, I had the 
opportunity to observe continuous glucose monitoring systems (CGMS) in situ. This led to 
deciding to explore how these novel devices could be used to make a difference to pwCF 
and their carers. This involved using and developing my existing research skills and 
experience of academic collaborative research, specifically, systematic reviews. From this 
initial engagement with pwCF, about what matters most to them about their diabetes and 
treatment, I further decided to use stakeholder engagement to devise outcomes for the 
review reflecting what patients themselves considered to be the most important factors 
rather than strictly clinical parameters of disease progress or status. 
 
1.1 Cystic Fibrosis 
Cystic Fibrosis (CF) is an autosomal-recessive genetic condition which affects multiple 
systems, primarily the lungs; leading to the main cause of mortality in people with the 
condition being respiratory failure (1). Multiple other bodily systems are also affected, most 
notably the digestive and reproductive systems. It is associated with Cystic Fibrosis Related 
Diabetes (CFRD); the most common extrapulmonary co-morbidity in people with CF (pwCF) 
(2). 
  
CF is one of the most common life-shortening disorders; patients with CF survive to a 
median age of approximately 47 years according to the Cystic Fibrosis Trust, with one in 
twenty-five people of northern-European descent estimated to carry the gene (3, 4). 
Globally, 70,000 people have CF and 1 in 2500 new-borns in the UK are estimated to be 
affected, leading it to be a particularly prevalent disease that carries significant morbidity 
and mortality. 
 
Pathological variation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
gene, located on chromosome 7, causes production of malfunctioning or non-functioning 
CFTR transmembrane proteins leading to the impaired transport of salts (especially 
[14] 
 
chlorides) across epithelial cell membranes within the body. The pancreas is one of the 
organs most frequently damaged by this pathology; progressive fibrosis and fatty infiltration 
resulting in insufficient pancreatic endocrine and exocrine activity and the most common 
comorbidity of CF being CFRD (5). CFRD will be discussed in depth later in this chapter. 
 
This imbalance in ion transport also leads to the inappropriate osmotic sequestration of 
water which manifests primarily through the production of excessively thick mucus at 
epithelial sites including the airways, reproductive organs, gastrointestinal system, 
hepatobiliary tract, and the pancreatic ducts. The thickened mucus secreted at these sites 
results in a variety of complications including recurrent and/or chronic bacterial colonisation 
leading to enduring inflammation which leads to fibrosis. It is this progressive fibro-cystic 
change in affected organs which results in deterioration of function over time, ultimately 
leading to significant morbidity and mortality in patients with CF.  
 
The most recent (2018) data report from the UK Cystic Fibrosis Registry (sponsored and 
managed by the Cystic Fibrosis Trust) estimates the median survival of pwCF born in 2018 to 
be around 44 years old for females, and 51 for males (1). The report states that while there 
has been a decreasing rate of mortality amongst people with CF over the last 30 years, the 
primary cause of death in this group remains to be cardiorespiratory failure, as in previous 
years (1). 
 
1.2 Diagnosis of CF 
There are several methods of identifying when a person has CF. It is commonly identified 
shortly after birth through a newborn bloodspot screening test, implemented in the UK 
since 2007. In some cases, CF is diagnosed antenatally through amniocentesis or chorionic 
villus sampling; identification of a meconium ileus on an ultrasound scan may raise 
suspicion of the presence of CF. If CF is otherwise clinically suspected, for example in a child 
with faltering growth or recurrent respiratory infections, this can then be confirmed 
through a positive sweat test or gene testing revealing two disease-causing variants. 
 
1.3 Cystic Fibrosis-related diabetes 
Cystic fibrosis-related diabetes (CFRD) is a particularly common comorbidity found in pwCF. 
As the life expectancy of pwCF improves, tackling CFRD presents a growing challenge to 
[15] 
 
patients and clinicians alike. This is due in part to the fact that prevalence of CFRD is 
associated with increasing age, with around 2% of children, 20% of adolescents and 50% of 
adults thought to have the condition (2).  The median age of onset is 20 years of age (6-8). 
Females are also thought to be at higher risk of developing CFRD and are likely to do so 
sooner than males (6, 9). In addition to age and sex, other risk factors for CFRD include a 
family history of type 2 diabetes mellitus, pancreatic insufficiency, CF-related liver disease 
and possessing a more severe genotype (10), which unfortunately includes the most 
common variant; ΔF508 (F508del) (11). 
 
Compared to pwCF who don’t have diabetes, people with CFRD (pwCFRD) experience 
significantly increased morbidity and mortality (by almost 6-fold (12)) with a substantial 
decline in lung function and nutritional status often being the first manifestation of the 
disease; beginning two to six years before a formal CFRD diagnosis by oral glucose tolerance 
test (OGTT) has been made (7, 11, 13-15).  Thus, CFRD presents unique challenges for 
clinicians, patients, and families alike, highlighting the vast need for accurate and timely 
diagnosis and effective management. 
 
Compared to other forms of diabetes, pwCFRD have an insulin deficiency with a delayed and 
diminished bolus response to carbohydrate loads, with sparing of basal insulin secretion. 
This contributes to normal fasting glucose and postprandial hyperglycaemia being a common 
occurrence in pwCFRD (16). The inappropriately delayed insulin response to a glucose load 
often leads to hypoglycaemia in pwCF who are not diabetic and can be observed on OGTT 
(17). The characteristic pattern of glycaemia in pwCFRD consists of glucose levels being 
lowest prior to breakfast, with peaks after each meal, and highest following the final meal of 
the day (16). A visual depiction of this pattern is available in section 1.5. 
 
1.3.1 The impact of CFRD on people with cystic fibrosis 
1.3.1.1 Survival 
As mentioned, CFRD is associated with significantly increased mortality, especially in 
females, compared to pwCF with normal glucose tolerance (NGT). 
 
1.3.1.2 Lungs 
Given that mortality in CF is often from progressive lung failure (1), perhaps the most 
important impact of CFRD on the morbidity and mortality of pwCF is the hastened decline in 
[16] 
 
lung function (forced vital capacity (FVC) and forced expiratory volume in one second (FEV1)) 
associated with insulin deficiency and hyperglycaemia. 
 
Inflammation of the airway epithelium, such as that seen in pwCF, increases epithelial 
permeability to glucose. When coupled with hyperglycaemia, which heightens the glucose 
gradient across the epithelial barrier, this can lead to an increase in the glucose 
concentration of the airway surface liquid that lines the lung (18). In some pwCFRD, a CGM 
reading of 8mmol/l an above has been linked to the detection of glucose in the airway 
surface liquid. The same study showed an increase in the growth of organisms such as 
pseudomonas aeruginosa and staphylococcus aureus when airway surface liquid glucose 
concentration rose to just 0.5-4mmol/l, likely contributing to pwCFRD experiencing an 
increase in infection and decrease in lung function (16). This could help explain why having 
CFRD is also linked to developing reduced gas diffusion, increased effort of breathing and 
more lung stiffness and structural disease than pwCF who have NGT (16, 19, 20). It is 
therefore likely that this pathology both contributes to and is exacerbated by an increased 
number of pulmonary exacerbations, inflammation of the airways, and bacterial colonisation 
as discussed (21, 22).  
 
1.3.1.3 Nutritional Status 
For pwCF, having a higher BMI is associated with reduced bone loss, maintaining  the  
immune system and having better lung function (23). This makes maintaining an individual’s 
target BMI a major goal in managing the treatment of pwCF; around 22kg/m2 for females 
and 23kg/m2 for males according to the Cystic Fibrosis Foundation (24). Good nutrition is a 
key part of managing CF, even in the absence of diabetes, and is achieved through nutritious 
high calorie diets devised and tailored by CF specialist dieticians within the multidisciplinary 
team (MDT). People with CF have higher resting calorie turnover and metabolic rate than 
the average person due to increased energy expenditure because of factors such as acute or 
chronic infection and increased work of breathing.  
 
Additionally, around 85% of pwCF are born with or develop pancreatic insufficiency before 
their first birthday, a hallmark of CF (25). This is when the exocrine function of the pancreas 
is below the level needed to allow a person to maintain their health without intervention. 
This means that most pwCF cannot adequately absorb carbohydrates, protein and, 
importantly, fats. Fats contain vital fat-soluble vitamins (A, D, E and K) and a high calorie load 
[17] 
 
meaning that pwCF are routinely given vitamin supplements and pancreatic enzyme 
replacement therapy to help meet their nutrition goals (26). This combination of 
malabsorption and high energy turnover leaves pwCF vulnerable to the substantial decline in 
nutritional status seen in CFRD.  
 
This is likely, in part, due to the characteristic insulinopenia; promoting a catabolic state 
which makes it more difficult for pwCFRD to maintain their lean body mass (11). This trait is 
also seen in people with T1DM but is likely exacerbated in CFRD by the additional pathology 
discussed above.  
 
1.3.1.4 Diabetic Ketoacidosis 
Diabetic ketoacidosis is a serious complication of insulin-dependent forms of diabetes. 
Fortunately, it relatively uncommon in CFRD as unlike in T1D, pwCFRD do not develop an 
absolute insulin deficiency; instead, retaining some basal insulin secretion (27). 
 
1.3.1.5 Hyperosmolar hyperglycaemic state 
Hyperosmolar hyperglycaemic state is rarely seen in CFRD (28). 
 
1.3.1.6 Macrovascular complications 
Macrovascular complications seen in other forms of diabetes are uncommon in pwCFRD. 
 
1.3.1.7 Microvascular complications 
Significant long-term complications such as retinopathy, nephropathy and neuropathy seen 
in CFRD are comparable to those observed in individuals with type 1 diabetes mellitus (29).  
While the prevalence of diabetic retinopathy and nephropathy in pwCFRD are lower than 
that seen in people with type 1 or type 2 diabetes, retinopathy still occurs in 10-23% of 
pwCFRD (29-31). PwCFRD are more likely than their non-diabetic counterparts to have 
autonomic neuropathy and may exacerbate the gastrointestinal dysfunction already 
experienced by many pwCF (30). 
 
These complications are dependent on disease duration as well as glycaemic control (11) 
thus, the American Diabetes Association (ADA) (28) recommends that CF patients known to 




1.3.1.8 Quality of life 
All the above complications have the potential to increase the burden of treatment and to 
adversely impact the quality of life experienced by pwCF. Having CFRD in itself can 
significantly reduce the health-related quality of life experienced by pwCF, and the addition 
of insulin therapy to their already intensive treatment regime significantly contributes to the 
overall treatment burden they experience (32). 
 
1.3.2 Screening and Diagnosis of CFRD 
Early diagnosis and optimisation of glycaemic control has been shown to vastly improve lung 
function, nutritional status and overall survival rates (2, 28, 33, 34), making regular screening 
from a young age a vital part of routine care of pwCF. 
 
Due to the high incidence of CFRD Amongst CF patients, the consensus between the Cystic 
Fibrosis Foundation (35) and the American Diabetes Association (28), as well as current NICE 
guidelines (14) state that people with CF should be tested for CFRD annually from the age of 
ten, especially as CFRD can begin to cause damage before a person starts experiencing 
symptoms (14, 36). Additional or earlier investigation is warranted if a patient is receiving 
long-term steroid treatment or experiencing unexplained weight loss, excessive fatigue, a 
drop in Forced Expiratory Volume in one second (FEV1) or increased frequency of pulmonary 
exacerbations despite receiving optimised CF treatment. PwCFRD can also experience 
polydipsia and polyuria as symptoms. 
 
Several screening tests have been used for CFRD: most commonly, the oral glucose tolerance 
testing (OGTT), serial glucose monitoring by capillary blood glucose (CBG) and continuous 
glucose monitoring (CGM) (14, 28). The appropriateness and utility of these methods for the 
diagnosis of CFRD are discussed in chapter 1.4.  
 
1.3.3 Pathophysiology of CFRD 
CFRD does share some clinical characteristics with both Type 1 and Type 2 diabetes (T1DM 
and T2DM, respectively) but is recognised as its own distinct condition (28). While both 
T1DM and CFRD are associated with a decline in insulin secretion, the autoimmune 
[19] 
 
pathogenesis noted in the former is not seen in CFRD; levels of antibodies in pwCF with NGT 
are the same as in pwCFRD (37). 
 
The pathophysiology of CFRD is multifaceted and still not fully understood. The overarching 
theme is that gradual destruction of the pancreas in CFRD leads to pancreatic insufficiency 
and insulinopenia, complicated by end-organ resistance to insulin (14). In CFRD, the typical 
viscous mucus produced in CF causes pancreatic duct obstruction; triggering inflammation 
and ischaemic changes, atrophy of the pancreatic islets, and progressive fibrosis and fatty 
infiltration within the endocrine pancreas (38-40). Destruction of the insulin-producing β-
cells causes insulin deficiency, reducing the ability of the pancreas to respond to post-
prandial increases in blood glucose leading to progressive glucose dysregulation and 
damaging hyperglycaemia. 
 
The CF-causing CFTR gene variants may also play a direct role in the development of CFRD 
as functional CFTR has been shown to be crucial for normal beta cell function (37). 
 
1.3.4 Monitoring and Management of CFRD 
Subcutaneous insulin is the mainstay of treatment while oral diabetes medications such as 
metformin and sulfonylureas are not usually recommended in CFRD (14, 28, 35). 
 
The ADA recommends that people with CFRD, who take insulin, should track their glycaemic 
control using the traditional CBG method at least three times a day (28). This data, obtained 
and noted by pwCFRD or their carers, is then collated by clinicians to evaluate an individual's 
overall glycaemic trends, allowing an individual’s CFRD treatment to be tailored to their 
specific individual needs. CGM is a newer form of monitoring glucose levels in diabetes (41) 
and investigating the utility of this in the context of CFRD forms the basis for this work. 
Rigorous monitoring of glucose levels facilitates the specific adjustments of elements of 
CFRD management including titration of insulin dosage and frequency, nutritional factors to 
improve clinical outcomes for pwCFRD. Thus, CFRD treatment is multidimensional and best 
confronted via an MDT approach. 
 
1.3.4.1 Insulin therapy 
Insulin is an anabolic hormone which stabilises and improves glycaemic control as well as 
lung function and reverses chronic weight loss decline experienced by pwCFRD prior to 
[20] 
 
diagnosis and treatment (33, 42). As in T1DM, insulin is the primary treatment for CFRD (28), 
but the associated targets and regimens differ from those used to tackle other forms of 
diabetes. 
 
For pwCFRD, multiple daily injections or insulin pump therapy is often required to achieve 
adequate reduction in hyperglycaemia. Because pwCF still produce some insulin, these 
doses tend be at lower quantities than those used in T1DM in order to safely counteract 
CFRD insulinopenia while avoiding inducing hypoglycaemia (43). 
 
The long-term benefit of optimising glycaemic control with insulin encompasses not only a 
delay in decline of lung function by 34 months on average (44), but also a reduction in 
microvascular complications (28). 
 
PwCF may have an increased insulin requirement during pregnancy, periods of taking 
corticosteroids, receiving enteral or intravenous feeds or during pulmonary exacerbations 
(35). A higher frequency of glucose testing also usually necessary during these events. 
 
1.3.4.2 Diet and exercise 
The earlier described specially balanced diet followed by pwCF should not be altered if they 
are diagnosed with CFRD (28). Instead carbohydrates should be monitored and insulin 
adjusted accordingly in order to optimise glycaemic control (28). 
 
Exercise is an important part of the health and wellbeing of the general population but 
conveys particular benefit to pwCF and pwCFRD in potentially helping maintain lung function 
and improve airway clearance (45). Exercise can reduce anxiety and depression for pwCFRD 
(46) and may also help reduce systemic inflammation and improve insulin sensitivity (47, 
48). To maximise these benefits, pwCFRD are recommended to do at least 150 minutes of 
moderate intensity aerobic exercise per week (28). 
 
1.3.4.3 CFTR potentiator and corrector therapy 
There is no clear consensus on the effectiveness of CFTR gene-therapy modulators, such as 
Ivacaftor, in aiding the prevention and/or treatment of CFRD (40, 43, 49-51). In recent years 
it has been suggested that modulators may have a favourable effect on incidence of CFRD or 
[21] 
 
insulin secretion (40, 43, 49), but there is still no conclusive evidence, necessitating further 
research in this area.  
 
1.3.4.4 Complications of CFRD management 
Hypoglycaemia can be a serious and potentially life-threatening risk associated with 
injectable insulin regimens, but may be less common and severe in CFRD than in other forms 
of diabetes (52). This less severe hypoglycaemia can often be treated by the individual 
themselves, with glucose tablets for example. Some pwCF who are not on insulin therapy 
can spontaneously enter this low-level hypoglycaemic state, likely due to a combination of 
malabsorption, increased calorie turnover and dysregulated or delayed insulin secretion 
(11). 
 
1.3.4.5 Impact on treatment burden 
PwCF dedicate a substantial amount of time and effort to multiple intensive treatment 
therapies, averaging 150 minutes per day (53), not including attending regular outpatient 
appointments or spending time in hospital as an inpatient during exacerbations.  This gives 
an idea of the significant treatment burden experienced by pwCF prior to a diagnosis of 
CFRD and the additional time and effort required to adequately monitor and manage 
glucose control that this brings. Mitigating the additional risks to health that CFRD poses 
involves adherence to an even more complex and rigorous treatment plan. As such it is 
important to investigate ways to reduce or simplify the significantly increased treatment 
burden experienced by pwCFRD compared to non-diabetic pwCF and to the general 
population (32). 
 
1.4 Diagnosis of CFRD 
CFRD should be diagnosed during a stable period of baseline health as acute illness or use of 
continuous enteral nutrition can cause fluctuating hyperglycaemia that may resolve when 
these stressors are overcome; this was previously termed ‘intermittent-CFRD’ (54). 
However, in patients with an acute illness who sustain fasting blood glucose or 2-hour post-
prandial plasma glucose levels above the ‘normal’ level (as detailed below) for over 48 




As mentioned, the most used diagnostic tests for CFRD include serial CBGs, OGTT and CGM. 
Routine CBG tests including serial random glucose readings above 11 mmol or fasting blood 
glucose (≥7.0 mmol/L) can be diagnostic of diabetes in pwCF (28).  
 
While HbA1c could in theory diagnose CFRD, the sensitivity of HbA1c as a 
screening/diagnostic test is controversial since it may remain within the normal range even 
while damage is occurring from hyperglycaemia, this is not a widely used diagnostic 
parameter for diabetes in pwCF (11). 
 
Although OGTTs are a relatively cheap method of screening for CFRD, there are several 
potential issues with the test. They can be time consuming and labour-intensive with 
multiple uncomfortable finger-sticks required over the course of one session. The values of 
an OGTT test indicating normal and abnormal glucose tolerance (NGT <7.8, IGT ≥7.8 - <11.1 
and diabetes ≥11.1mmol/L at 120-minutes) are drawn from a non-CF diabetic population 
who are thus geno-typically different. These existing diagnostic criteria for diabetes were 
based on the WHO criteria and the risk of developing micro-vascular complications in T2DM 
(55) rather than CF specific outcome. There is evidence that the 120-minute value fails to 
discriminate between healthy controls and those with CFRD (56). As the OGTT also has poor 
sensitivity and specificity in diagnosing CFRD (57), the applicability of the test in this context 
could be contested. For these reasons, it has been suggested that the diagnostic limits of this 
test in a CFRD context should instead be guided by the ‘pulmonopathy’ that occurs at very 
low level hyperglycaemia in pwCF (57). To mitigate the poor sensitivity and specificity of 
OGTTs in the diagnosis of CFRD, NICE guidelines recommend that an abnormal test be 
followed up with dynamic testing, such as serial CBGs or CGM for confirmation (14). 
 
Performing an OGTT to diagnose CFRD in medically stable pwCF is currently recommended 
by the European Cystic Fibrosis Trust (35), the UK CF Trust (58) and ADA (28). NICE have 
recently updated their advice to include CGM as a valid diagnostic tool alternative to OGTT, 
























Figure 1: Methods of diagnosing CFRD (14, 28) 
1.5 Continuous glucose monitoring 
Continuous glucose monitoring systems (CGMS) are a relatively recent development and 
offer a less invasive alternative to CBG and work by transmitting blood glucose values, 
calculated from actual interstitial fluid glucose concentrations, measured by a subcutaneous 
sensor, to a display device or smart phone. Thus, unlike CBG, CGM reflects an individual’s 
glucose trends rather than absolute plasma glucose levels (11). Because of the lesser 
accuracy of CGMS readings in the lower range, these values need to be cautiously 
interpreted. The International Consensus on Use of Continuous Glucose Monitoring have 
suggested the following ranges of CGMS data values are used to categorise hypoglycaemia 
severity (60): 
 
Category of hypoglycaemia Presentation Indication 
Level 1 3.9-3.0mmol/L  
(with or without 
symptoms) 
• At risk of impending 
hypoglycaemia 
• Reduce time spent at 
this level to reduce 
Medically stable pwCF (outpatients) 
• OGTT (including annually from 10 years old) 
o ≥11.1mmol/L at 120 minutes post glucose 
load 
o To be confirmed by dynamic testing if 
abnormal e.g. with CGM 
• CBG 
o Serial random glucose: ≥11mmol/L 
▪ Or: one random glucose reading 
≥11mmol/L accompanied by 
symptoms of hyperglycaemia  
o Fasting plasma glucose: ≥7.0mmol/L 
• HbA1c (not recommended for screening) 
o ≥48mmol/mol 
PwCF who are pregnant or planning to become pregnant 
• OGTT: 2-hour 75g fasting 
o Where pwCFRD are confirmed to be pregnant or 
planning to become pregnant and have not had a 
normal OGTT screen in the previous 6 months 
o Routinely performed at both 12-16 weeks and 24-
28 weeks gestation to screen for gestational 
diabetes mellitus 
▪ NICE 2017 guidance suggests CGM 
could be used as an alternative to 
OGTT in this case 
o Where gestational diabetes is diagnosed in a 
pwCF, a further OGTT to assess for CFRD at 6-12 
weeks postpartum should be performed 
 
Acutely ill (receiving intravenous antibiotics or glucocorticoids) 
• Hyperglycaemia that persists ≥48 hours 
o Fasting plasma glucose ≥7.0mmol/L 
o 2-hour post-prandial glucose ≥11.1mmol/L 
• Where these readings are obtained by CBG, they must be 
confirmed by a certified laboratory 
PwCF receiving continuous enteral feedings 
• Glucose readings of ≥11.1mmol/L  
• Readings taken mid-feed or immediately post-feed when 
initiated and monthly thereafter 
o At least two separate abnormal results 
obtained  
Diagnosis of CFRD 
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risk of further 
hypoglycaemia 
Level 2 3.0 mmol/L 
(with or without 
symptoms) 
• Clinically significant 
hypoglycaemia 
• Immediate attention 
required 
• Given more weight in 
clinical studies than 
Level 1 
Level 3 Severe hypoglycaemia  





Table 1: Categorising hypoglycaemia identified by CGMS (60). 
 
The sensor is inserted into the subcutaneous tissue of the individual's arm or lower 
abdomen by the individual or their carer and is then left in-situ for at least 72 hours or up to 
10 days at a time. This provides semi-continuous 24-hour information, from glucose 
readings taken every five minutes, regarding glycaemic changes and trends through day and 
night, accumulating substantially more data than intermittent CBG monitoring.  
 
For people using some older models of CGMS, it is sometimes recommended that they 
perform CBG at least once every 12 hours to calibrate the device. Some newer devices no 
longer require this input (61). A diary is kept tracking events with the potential to trigger 
significant glycaemic fluctuations such as: dietary intake, exercise (especially if vigorous), 
the consumption of sugary drinks, and administration of hyper/hypoglycaemic drugs, 
though this is not always necessary. This data can then be analysed and reconciled with 
glycaemic variability. 
 
Below is an example of part of a CGM trace from a young person with CFRD who has 




Figure 2: Abnormal CGM trace in a pwCFRD recently started on insulin therapy 
Although the ‘median’ trace stays within the wearer’s target range, the upper range of their 
glucose profile across the weeks of CGM data indicates that they have still spent time in the 
hyperglycaemic range. Where the apple icons are situated below the trace marks when the 
wearer has had a meal, the typical postprandial hyperglycaemia experienced by pwCFRD is 
illustrated by delayed peaks in glucose after each of these, of increasing amplitude 
throughout the day. There is little or no indication that this person has experienced 
hypoglycaemia during this CGM trace as the lower limit of the normal glycaemic range has 
not been crossed. 
 
For comparison, a normal CGM trace might look like this: 
 
Figure 3: A normal CGM trace 
In this trace, even across the several weeks that the CGM was recording glucose data, the 
wearer has had a gradual increase in glucose throughout the waking day, but never strays 
outside of their normal glucose range. 
 
1.5.1 CGMS to diagnose CFRD 
While CGMS were developed for monitoring glucose control in those with T1DM, these 
systems have recently emerged as a useful validated tool to diagnose CFRD (14, 62, 63). 
Because CGM collects data across a period of several days, it is likely a reliable way to 
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detect hyperglycaemia due to the variable nature of glucose dysregulation (14), and this is 
increasingly reflected in its use in clinical practice and inclusion in some major diagnostic 
guidelines (14). Other guidelines remain unchanged, citing that further work is needed to 
illustrate the effect of diagnosis through CGM on long term outcomes before it can be fully 
endorsed (59, 63). 
  
1.5.2 CGM to monitor CFRD 
CGM has been recommended as a form of glucose screening by the most recent NICE CFRD 
guidance (14). There are two main types of CGMS equipment and analysis: real-time versus 
retrospective data presentation.  
 
‘Unblinded’ or real-time CGMS provide information to guide diet, exercise, and insulin 
therapy as an alternative or supplement to CBG, potentially reducing the discomfort and 
inconvenience of otherwise more frequent finger sticks. Some ‘true’ real-time CGM models 
integrate alerts for glucose levels above or below a pre-set threshold allowing immediate 
remediation of significant glycaemic fluctuations, whereas others require the user to scan 
the CGMS to obtain a glucose reading (intermittently scanned CGM). 
 
‘Blinded’ or retrospective CGMSs similarly allow more detailed data trends to be observed 
than CBG but do not allow for immediate modification of glucose-altering factors in the way 
that real-time CGMS do as glucose levels are not displayed in real-time. These devices are 
worn for a period of time and the resulting data is  considered by clinicians and patients 
together to assess overall glycaemic trends (62). However, when used in conjunction with 
diabetes management education and insulin dose adjustment, blinded CGM has been 
shown to aid the monitoring and management of other forms of diabetes, but not CFRD 
(62). 
 
CGMS has been validated as a tool to both diagnose CFRD and proposed as a strategy to 
better manage CFRD than traditional means; potentially conveying benefits to patients’ 
weight and lung function as discussed (64). However, the impact of CGMS-guided insulin 
regimens on the lives of people with cystic fibrosis related diabetes remains unclear (65).  
Thus, the focus of this dissertation aims to address the question; “What is the evidence that 
CGM-lead treatment modification improves outcomes for pwCF diagnosed with CFRD?” 
[27] 
 
2. Evidence-based medicine and the systematic review 
The world of medicine is complex and ever-changing. With novel healthcare treatments and 
advancements in therapeutic technologies emerging all the time, there is a need for the 
availability of up-to-date data evaluating the benefits and harms these interventions can 
bring, as well as identifying what the most appropriate therapies are within different clinical 
contexts. Practicing evidence-based medicine integrates clinical expertise with the best 
available external evidence (66), ensuring that informed decisions can be made in the best 
interests of a person’s health and wellbeing.  
 
However, with an ever-expanding wealth of such literature, often with inconsistencies 
across the final conclusions presented, systematic reviews (SRs) can offer a critical appraisal 
and summary of a large body of primary research to ascertain the overall answer to a 
specific question to assist individuals in their decision making. SRs of randomised controlled 
trials (RCTs) with meta-analysis represent the top tier in the hierarchy of evidence (67); 
summarising all the best available research to provide reliable estimates about the effects of 
an intervention, or demonstrate where a lack of knowledge on a subject exists and thus 
highlighting where future research should be directed. 
 
2.1 What are systematic reviews and meta-analyses? 
Undertaking a SR is a method of stringently identifying, critically appraising and collating all 
the available evidence across different studies to answer a pre-defined question in a 
methodical and reproducible way. To help reduce bias and ensure reliable conclusions are 
drawn, SRs are constructed around several defining features (68). 
 
An explicitly recorded methodology is a key foundation for any SR and should be determined 
before the initiation of data collection; it should be watertight enough that peers may 
replicate the process, exactly as the original researcher performed it.  
 
The literature search process should be systematic, ensuring all appropriate sources are 
explored to identify all studies relevant to the review question. The objectives of the SR, as 
well as the criteria by which studies will be excluded or determined eligible for inclusion, 
must be defined ‘a priori’ and should be stated clearly. The processes of assessing validity of 
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included studies as well as then extracting, synthesising, and reporting the data collected 
must be performed in a methodical fashion. 
 
Meta-analysis is a method of statistically comparing and integrating the effect estimates and 
confidence intervals (CIs) from studies included in the review that are sufficiently like one 
another. It is often performed as part of the data analysis of an SR to draw conclusions about 
the total body of research. Meta-analyses can illustrate whether there is an overall benefit 
from the new intervention in comparison with a control i.e. usual care or placebo and 
whether this difference is a truly significant one or a reflection of the effect of random 
chance. 
 
This illustration can be quite literal in the form of a forest plot, summarising key data from 
multiple studies into a single diagram to facilitate visual comparison of the range of 
treatment effects estimated in the literature. In a forest plot, the horizontal x axis represents 
the extent to which a study’s results favour the intervention or the control, in a scale 
appropriate for the statistic being displayed such as an odds ratio or relative risk where a 
‘relative’ statistic is concerned, versus absolute values scaled in absolute risk reduction or 
standardised mean difference. For relative values, at (1.0) on the x axis lies the vertical y 
axis; representing the line of null effect where there is no difference in outcome regardless 
of exposure to either intervention. Alternatively, for absolute values, the line of no effect 
intersects the x axis at (0.0).  
 
Each study included in a forest plot is represented by a block, the position of which indicates 
a point estimate of its results, whereas the size of the block signifies the weight assigned to 
that study in the meta-analysis based on factors such as the number of participants involved. 
A horizontal line extends through each block, the width of which indicates the CIs for each 
study concerned; a wider line indicates a less reliable a study’s findings are likely to be.  
If outcome being measured is desirable, such as improved lung function, results that sit to 
the right of the line of no effect indicate that exposure to the intervention of interest 
positively affected that outcome, compared to the control group. If the outcome being 
measured is undesirable, results to the left of the line indicate that the intervention of 





Figure 4: An example of a forest plot comparing relative change in % predicted FEV1 for azithromycin versus 
placebo. From ‘Macrolide antibiotics for cystic fibrosis’ by Kevin W Southern et al. 2004 (69) 
 
The diamond at the bottom of a forest plot is a combined average of all the studies in the 
graph and functions in a similar way to the blocks, with its width indicating the spread of the 
results between 95% CIs; the range of values in which we can be 95% certain that the true 
treatment effect lies. For this reason, smaller diamonds are an indication of greater 
confidence in the true effect. Diamonds can be interpreted from the diagram similarly to the 
results of individual studies as detailed above, however if any part of a diamond lies across 
the line of null effect, it indicates that the results are not statistically significant and so the 
intervention of interest does not make a meaningful difference to the outcome measured 
compared to the control group. 
 
Studies that are investigating the same intervention and are recording similar outcomes 
should theoretically produce similar results. By visually representing the degree to which the 
results of studies overlap, or fail to do so, forest plots can give an indication of the presence 
of heterogeneity. Random variation can account for some differences between findings, but 
where overlap of studies on a forest plot is minimal, heterogeneity should be investigated 
and its potential effect on overall conclusions examined (68). Alternatively, where there is a 
significant amount of overlap in the same direction, the lack of variation of results can 
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indicate that they are more likely to demonstrate an accurate estimate of the true effect, a 
reflection of homogeneity. 
 
2.1.1 Heterogeneity 
Heterogeneity is the term used to describe causes of variation between the results of studies 
and can mainly be categorised as; clinical, methodological, or statistical heterogeneity. 
 
• Clinical heterogeneity can be defined as the normal variation between the 
characteristics of participants in different studies such as age or severity of disease. 
It also accounts for diversity in certain features of the interventions studied such as 
method of delivery or dosage. 
 
• Methodological heterogeneity refers to the fact that different study designs can 
yield different results e.g. a cluster-randomised trial vs. a cross-over trial. It can also 
arise from studies differing in how they record and interpret outcomes such as time 
points at which measurements will be taken, or studies with differing levels of risk of 
bias being inappropriately combined. 
 
• Statistical heterogeneity can be caused by clinical heterogeneity and/or 
methodological heterogeneity and represents the random variation that occurs due 
between results of studies when they are measuring potentially similar but less-than 
identical effects. Excess variation can indicate that the effects studied may have 
been too significantly different to appropriately combine in a meta-analysis. 
Statistical heterogeneity is thus the type usually referred to when meta-analyses or 
systematic reviews discuss ‘heterogeneity’. 
 
2.2 Why perform a systematic review? 
There are many advantages to SRs providing a comprehensive overview of the available 
literature on a specific topic, often supported by data synthesised through meta-analyses. 
They condense what can be an overwhelming number of studies, likely of varying quality and 
validity, into an accessible quality-assessed summary to aid evidence-based decision-making 




As a part of this process, SRs can help determine when sufficient investigative evidence has 
been collected to adequately resolve a research question, thereby reducing the need for 
further studies in that area, saving time and resources. When a clinical question has been 
satisfactorily answered, the SR can establish relevant implications for clinical practice and 
influence clinical guidelines, thus supporting the practice of evidence-based medicine. 
 
Conversely, SRs can highlight where there is a lack of evidence on a topic, when few or no 
RCTs are found to be eligible for inclusion in an analysis, sometimes known as an ‘empty 
review’. These empty reviews can still play an important role in medical research as in 
highlighting gaps in the knowledge base, they can provide a direct starting point upon which 
future clinical trials can be based. This has often been the case in Cochrane SRs about CF. 
(70) The Cochrane Cystic Fibrosis and Genetic Disorders (CFGD) group have collated a list of 
published empty SRs and the resulting major ongoing RCTs and completed RCTs that have 
led to changes in practice (71). One such example is a Cochrane SR entitled “inhaled 
corticosteroids for cystic fibrosis” (72) which prompted the CF WISE trial (73) run by Balfour-
Lynn et al. which demonstrated the safety of stopping inhaled corticosteroids for some 
pwCF, reducing drug burden, side-effects and reducing costs. 
 
Because RCTs are the gold standard for primary research into the effectiveness of an 
intervention (74), it follows that SRs of RCTs and the data they produce are considered as 
being better than other study designs in the hierarchy of evidence collection and can be 
viewed as a lens through which other studies can be collated and critically appraised (67). 
SRs can explore and resolve inconsistencies in results to give insight into what the true 
treatment effect is. For example, through meta-analysis, the process of weighting studies 
provides a clearer depiction of the precision of individual studies which can help readers to 
weigh up conflicting findings. 
 
2.3 Limitations of a systematic review 
The rigid methodological approach of SRs means that it is unlikely that all variations in 
circumstances, such as those present in day to day clinical practice, can be fully taken into 
consideration. SRs aim to answer a specific question, therefore if someone seeking 
information on a similar but unidentical topic, e.g. the same drug but in elderly patients, the 
evidence from the SR is indirect. This emphasises the need for clinical judgement to be 




Where the literature base of individual studies investigated by the SR is biased, the SR itself 
will be biased (75) but by aiming to access unpublished literature, this bias may be mitigated 
to an extent. Where heterogeneity in findings is observed, it is important that the sources of 
this are investigated as this may reduce confidence in the effect estimates produced and 
undermine the credibility of the review. 
 
Accurate quality assessment on the validity and risk of bias of studies can be challenging, 
particularly as methodology and data can poorly described in the literature. Cochrane 
authors are encouraged to contact the authors of included studies where data is missing in 
order to mitigate this, though it has been recognised in a Cochrane methodological review 
that efforts may not always be successful, particularly where older studies are concerned 
(76).  
 
2.4 The Cochrane Collaboration 
The Cochrane Collaboration is an independent, not-for-profit group that regularly produces 
and updates comprehensive systematic reviews from thousands of members across 130 
countries for the last 25 years. These reviews support and inform evidence-based decision-
making about healthcare issues (77). The organisation was founded in 1993 in the name of 
British epidemiologist Archie Cochrane, considered by some to be the ‘father of evidence-
based medicine’ (78).  
 
Dr Cochrane advocated for the inclusion of scientific evidence to guide medical practice 
within the NHS both in terms of treatment effectiveness and in appropriate allocation of 
resources (78). He advocated for and highlighted the importance of RCTs as an important 
source of evidence to substantiate the use of medical interventions, believing it to be more 
reliable than that from other sources (77). 
 
The Cochrane Collaboration has formulated a stringent process, adherence to which allows 
high-quality SRs to be produced and this process is denoted in full in the ‘Cochrane 
Handbook for Systematic Reviews of Interventions’ (68). Demanding a reproducible protocol 
to be devised before a literature search can be carried out, alongside their rigorous editorial 
and peer-review processes, minimises the risk of bias affecting the SRs and ensures the 
results produced are reliable and credible (68). Consequently, Cochrane reviews are 
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regarded as the international quality benchmark for evidence regarding health care 































3. Methodology for the CFRD Cochrane systematic review 
3.1 Background 
CGM has been validated as a novel tool to diagnose and manage CFRD earlier and more 
effectively than through traditional means (64), but the impact of CGMS-guided insulin 
regimes on the lives of people with cystic fibrosis related diabetes remains undetermined 
(59). A previous Cochrane review “Continuous glucose monitoring systems for type 1 
diabetes mellitus” (79) evaluated the same health technology in patients with T1DM which 
has since been used to inform 6 clinical guidelines (80-85) on the appropriateness of CGM 
use in this context. As described, CFRD has similarities to T1DM, however it is still 
fundamentally a separate condition with unique features and so the data from this review 
cannot be directly extrapolated to inform the use of CGM in pwCFRD. 
 
This work represents an original systematic review designed to investigate the impact, or 
lack thereof, of using continuous glucose monitoring systems to monitor glycaemia in 
CFRD. In particular, it was designed to evaluate whether modification of a person’s insulin 
regime (dosage, frequency, type of insulin administered etc.) guided by CGMS-collected 
data could affect the clinical outcomes and quality of life experienced by pwCFRD 
differently than traditional therapy i.e. insulin treatment guided by CBG.  
 
3.1.1 Description of the intervention 
CGMSs have been around since the late 1990s / early 2000s (86), with new and improved 
models being released by different brands semi-regularly since. Primarily used in non-CF 
diabetes, CGM has been validated as being comparable in CFRD (65, 87). 
 
The devices record interstitial fluid glucose levels up to 288 times per 24 hours for at least 
three to five days, accumulating substantially more data than intermittent CBG monitoring. 
From this we can build a much more detailed picture of an individual’s glycaemic variability 
across the day and at night to help patients and clinicians make decisions about how to best 
tackle hyperglycaemia. 
 
As detailed earlier in this thesis, CGMS have two major subgroups: real-time versus 
retrospective data presentation. Real-time or ‘flash’ CGMS readings can be viewed instantly, 
or the complete data set can also be downloaded to view retrospectively. On the other 
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hand, with retrospective CGMS, glycaemic data cannot be viewed immediately but can be 
downloaded to be analysed retrospectively. Both types were considered under the CGMS 
umbrella as a single intervention for the purposes of this review. 
 
3.1.2 How the intervention might work 
PwCFRD who take insulin are usually advised to perform and record CBG measurements a 
minimum of 3 times a day, with extra measurements also being necessary when 
experiencing symptoms of hypoglycaemia or before exercising.  
 
CGM is a more recently developed and detailed form of glucose monitoring, sometimes used 
by people with T1DM (88), and investigating the utility of this in the context of monitoring 
CFRD forms the basis for this work. The data collected through these methods can be used 
by clinicians to titrate the doses, frequency of administration or type of insulin a pwCFRD 
takes to tackle hyperglycaemia and avoid hypoglycaemic events to improve outcomes (11). 
In theory, the maximal data sets produced by CGM could facilitate more precise changes to 
optimise treatment regimens since they may pick up glycaemic excursions that may be 
missed by the glycaemic snapshots taken with CBG monitoring.  
 
The instant information available to pwCFRD using real-time or flash CGMSs, as an 
alternative or supplement to CBG, could help them tailor their diet, exercise, and insulin 
therapy more accurately. It could also offer an educational opportunity in terms of being 
able to visualise how different triggers affect their blood sugar levels and may reduce the 
discomfort and inconvenience of otherwise more frequent finger sticks. With both types of 
CGMSs, the wealth of data on an individual’s insulin needs and responsiveness can be 
downloaded to be analysed by clinicians retrospectively.  
 
UpToDate, an American advanced clinical decision support tool, has suggested that CGM can 
also be beneficial for pwCFRD who are not responding to standard therapy as well as 
expected, i.e. poor weight gain despite initiation of insulin therapy (11).  
 
In theory, if the rigorous monitoring of glycaemic changes provided by CGM can help 
prevent or reduce hyperglycaemia in pwCFRD through facilitating more precise adjustments 
to therapy elements, particularly the insulin regime, this could improve key outcomes in 
pwCFRD including lung function and weight gain. 
[36] 
 
3.1.3 Why it is important to do this review 
This review seeks to establish the impact of novel CGMS-guided insulin therapy (insulin 
regimen modification in response to CGMS excursion data) on the lives people with CFRD 
in comparison to insulin therapy guided by other forms of glucose data collection.  
 
People with CF are a group of individuals with a high burden of treatment which increases 
with age, therefore trying to find ways of streamlining treatment to reduce this where 
possible is an important area to investigate (89, 90). As such, it is important to establish 
the impact of CGMS-led insulin tailoring on aspects of health and life that people with 
CFRD themselves consider to be particularly important, as depicted in the outcomes for 
this review. Implementing use of CGMS equipment is currently costly (14) even though 
this price is falling (91), and so it is not currently available everywhere. This further 
highlights the importance of making evidence available to stakeholders and funding 
bodies regarding the effectiveness of this health technology (14). 
 
The topic “continuous glucose monitoring systems for monitoring CF-related diabetes” 
was previously listed as a priority review title by the Cochrane Cystic Fibrosis and Genetic 
Disorders group in March 2019 (92), highlighting the need for a review of evidence based 
research on the topic. The list has since been updated to reflect the title having been 
addressed by this review. 
 
3.1.4 Objectives  
To evaluate the impact of continuous glucose monitoring-guided insulin regimens, both 
positive and negative, on the lives of people with cystic fibrosis related diabetes 
(pwCFRD) according to outcomes considered important by pwCFRD. 
 
3.2 Stakeholder engagement and patient involvement 
For the purpose of cultivating a set of outcomes that would make meaningful difference to 
the lives of pwCFRD and their families, it was decided that stakeholder engagement would 
be undertaken, in the form of a semi-structured interview, to ascertain which outcomes 




The stakeholders that were consulted for this review encompassed a variety of clinicians 
including CFRD specialist Advanced Nurse Practitioners and respiratory and CF specialist 
consultant and trainee physicians as well as ten individuals with CFRD and their families. This 
work was commenced in three clinical areas across two hospital sites to ensure that a 
variety of patients and clinicians were involved in the consultation process. These sites 
included a paediatric CFRD-specific CF clinic in Alder Hey Children’s Hospital as well as both 
an adult CFRD outpatient clinic and an adult CF inpatient ward in Broadgreen Heart and 
Chest Hospital.  
 
This variation in stakeholder recruitment environment meant that the pwCFRD also varied in 
both age and degree of disease severity, it was hoped that this could give a broader outlook 
on issues that matter to pwCFRD at different points in their lives. The selection of pwCFRD 
who were interviewed was based on who attended clinic or was on the ward on the day that 
the interviewer was present, who were also happy to partake in the discussion. A simple 
interview template of open questions was formulated beforehand, to guide the meetings, 
that was based on the combined clinical experiences of the review authors with the aim of 
exploring which aspects of their treatment mattered the most to pwCFRD. 
 
Key themes highlighted through discussions with clinical staff largely revolved around the 
importance of preserving and improving lung function first and foremost, as well as other 
clinical parameters including maintaining in-range blood glucose values and the prevention 
of long term CFRD-related adverse outcomes. The discussions held with pwCFRD and their 
families carried a similar message but focussed on more wholistic aspects of the experience 
of patients. This raised key issues such as the amount of time pwCFRD were absent from 
school or work due to health-related issues, the additional burden of treatment that comes 
with the diagnosis of diabetes and how well an individual felt able to manage their condition 
and treatments independently. Maintaining their BMI and preventing weightloss was 
mentioned by every pwCFRD that was interviewed, viewed as their own indicator of how 
well they were doing with their condition, i.e. patients linked maintenance of body mass 
with better lung function, a lower rate of respiratory infections and being an indicator that 
their diabetes was under control. The frequency of this concern amongst pwCFRD clearly 
illustrates the importance of weight and BMI as a particularly meaningful outcome to them 




The subsequent discussion of these aspects of patient experience furthered the authors’ 
interest in the impact of CGM on the overall quality of life experienced by pwCFRD and 
contributed to this being prioritised as a primary outcome. The engagement process helped 
inform the decisions of authors in establishing and appropriately ordering subsequent 
outcomes for the Cochrane review, to improve the relevance of this review to consumers, as 
well as to inform ourselves as researchers. 
 
3.3 Methods 
3.3.1 Searching for studies 
Ideally, the Cystic Fibrosis Trials Register search would be conducted by the Cochrane 
CFGD's Information Specialist. However, due to the time constraints of the MPhil and 
delays caused by the COVID-19 pandemic, this search was undertaken by author, AT. 
Relevant studies were sought using the terms: cystic fibrosis-related diabetes [CFRD] and 
impaired glucose tolerance [IGT], in accordance with the protocol. The Cystic Fibrosis Trials 
Register is an amalgamation of all clinical trials to date that concern CF; the register is 
maintained by the Cochrane CFGD group who regularly update it with studies found during 
frequent electronic searches of the Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE and Embase. Trials added to the register are also identified through 
regular hand-searching of Pediatric Pulmonology and the Journal of Cystic Fibrosis and 
unpublished work is also sought from the abstract books of several key cystic fibrosis 
conferences for addition to the collection.  
 
Additionally, the protocol stipulated that we intended to search the following databases 
and trial registries for relevant literature: 
 
• Embase Healthcare Databases Advanced Search (HDAS) (1974 to present; 
https://hdas.nice.org.uk/); 
 
• Web of Science Core Collection (1900 to present); 
 





• Australian New Zealand Clinical Trials Registry (ANZCTR) (www.anzctr.org.au); 
 
• World Health Organization International Clinical Trials Registry Platform (WHO 
ICTRP) (apps.who.int/trialsearch). 
 
The bibliographies of included studies and relevant systematic reviews would be examined 
for further references to applicable trials to ensure that no studies eligible for inclusion 
would be overlooked. Our search strategies were cultivated by the team of authors with 
input from the Cochrane CFGD information specialist to maximise the scope of the search 
and obtain all relevant trials. Details of our full search strategies can be found in the 
appendices. 
 
Unfortunately, the unprecedented events surrounding the advent of the COVID-19 
pandemic from March 2020 meant that access to the WHO ICTRP became restricted to staff 
within the WHO. This occurred during the initial data collection phase of the Cochrane 
review, mandating that this database was omitted for the purposes of this thesis due to time 
constraints. Despite this, every effort will be made to incorporate search results from the 
ICTRP into the final version of the systematic review before submitting it for publication. 
 
3.3.2 Assessing eligibility for inclusion 
Two review authors; AT and AM; independently applied the predetermined selection 
criteria to identify potential studies to be included for review, in line with the standards 
set out by Cochrane (68). A new data collation spreadsheet was created by AT to aid the 
screening of papers and for ease of comparison between the decisions made by AT and 
AM. The inclusion criteria we used for this process are to be peer reviewed and then 
published via the protocol in the Cochrane database to help minimise bias and to 
enhance the transparency of the research (93). The criteria considered the following 
aspects: 
 
• Appropriate study design- All randomised controlled comparisons were 
included. Studies with a cross-over design, even with a washout period between 
intervention arms, were not eligible for inclusion due to the potential long-term 
impact of each of the interventions and thus potential to compromise the 




• Relevant participants - We included pwCF of any age who also had a diagnosis of 
CFRD as determined through the benchmarks discussed in Chapter One. There 
were no specific exclusion criteria for pwCFRD*. 
 
• Relevant interventions - We were looking at the effects of insulin regimens led 
by CGMS data (including real-time or retrospective data, or both) as compared 
to insulin regimens guided by other means of glycaemic data collection. This 
included but was not limited to insulin regime modification in response to CBG 
monitoring by finger stick. Types of CGMS and comparators were eligible for 
inclusion regardless of the associated insulin dosage, frequency, or mode of 
delivery. 
 
• Relevant outcomes - The outcomes of particular interest to the study are 
explored in the section below, however, if a study was identified as being 
relevant to the research question but did not report on the outcomes listed, this 
would not have warranted exclusion from the review and so it would still have 
been evaluated as part of this piece of work. 
 
Using these parameters, the resulting titles and abstracts of these articles were initially 
screened, followed by analysis of the full text of studies determined to have the 
potential to meet the inclusion criteria. Where information needed to determine 
eligibility for inclusion was missing, or when only an abstract of an otherwise potentially 
eligible study was obtainable, we contacted the investigators (Stackhouse (94) and 
Jackson (95)) to attempt to retrieve the necessary data to clarify the inclusion status of 
the relevant papers. We aimed to resolve differences in opinion on inclusion through 
discussion where possible, or through referral to a third author for consensus when 
necessary. 
 
*Where relevant studies containing mixed-participant samples would be identified (e.g. 
people with type 1 diabetes and people with CFRD included), the full review group 
would discuss on a case by case basis whether the studies should be included. If the 
consensus were that any such study should be included in the review, the relevant 
authors would be contacted to try and obtain the relevant specific subgroup data on the 
[41] 
 
CFRD patients for inclusion in the review. Where authors were unable or unwilling to 
provide the relevant data, these studies would not be included in any meta-analysis. 
 
3.3.3 Outcomes recorded 
To determine the following outcomes, previous papers related to the topic were reviewed 
and stakeholder engagement was undertaken as previously described. The outcome 




1.       Quality of life (QoL) (measured by a validated disease specific tool e.g. CFQ-QOL(96)) 
2.        Treatment-related adverse outcomes (e.g. hypoglycaemia (defined as ≤ 3.8 mmol/L), 
contact dermatitis etc) 
 
Secondary outcomes 
1.         Lung function 
a) FEV1 % predicted (change from baseline or absolute post-treatment values) 
b) FEV1 L (change from baseline or absolute post-treatment values) 
c) change in lung function as measured by another valid parameter 
2.   Nutritional parameters 
a) weight (kg or percentile) 
b) body mass index (BMI) percentile 
3.   CFRD-related adverse outcomes (e.g. diabetic ketoacidosis (DKA), hyperosmolar 
hyperglycaemic state, microvascular disease and hypertension, diabetic nephropathy, 
retinopathy and neuropathy, mortality) 
4.   Proportion of time within a normal blood sugar profile (*≥7.8 mmol/l ≥4.5% of time 
<70–54 mg/dL (3.9–3.0 mmol/L) 
5.   Burden of treatment 
6.   Self-efficacy** (as measured using a standardised scale e.g. General Self Efficacy 
Scale (97)) 
7.   Time off school or work (self-reported or otherwise documented) 
 
* 'Normal' range can vary between individuals  
[42] 
 
**  Self-efficacy for the purposes of the review was defined as the extent to which an 
individual could (or felt confident in their ability to) manage the monitoring and 
treatment of their medical condition independent from their carer/parent or medical 
staff etc. 
 
3.3.4 Data Extraction 
Data extraction forms based on those provided by the Cochrane editorial team were 
customised by AT to aid independent data extraction by the authors. This would help 
present the data for synthesis in a more structured, organised manner. 
 
Where differences in opinion occurred on the suitability of a study or its risk of bias, these 
would be resolved through discussion where possible, or through referral to a third author 
(DN) for consensus if necessary.  
 
Included studies would be analysed and the following information extracted and collated 
into the data extraction form for each: 
 
• Administrative information including first author, year of publication, country, 
language. 
• Study participants including number of included participants in each group and 
their baseline characteristics such as age and sex, as well as the diagnostic criteria 
used and the regions from which participants were recruited. 
• Study characteristics including design of study; recruitment and sampling 
procedures, inclusion and exclusion criteria, duration of follow up, outcome 
measures. 
• Details of intervention techniques used for collection of the glucose level data and 
the corresponding insulin-dosage modification strategies. The integrity of 
interventions applied is also important to note; the degree to which interventions 
were implemented as planned e.g. how many days/hours of usable CGM data 
were collected. 
• Data to address the primary and secondary outcome measures as prespecified in 
the protocol and the measurement tool used to assess these and the time points 




These outcome data would be reported within several timeframe groups to account for 
variation in length of follow-up between studies: 
 
1. up to two weeks 
2. over two weeks and up to one month 
3. over one month and up to three months 
4. over three months and up to six months 
5. over six months and up to one year 
6. annually thereafter 
 
Authors of studies including a subset of relevant data or missing data would be contacted for 
further information so that all available published or unpublished data on from included 
studies are included in the systematic review. 
 
3.3.5 Risk of bias 
Two review authors; AT and AM, would independently assess the risk of bias of studies to 
be included for review. The Cochrane Collaboration’s tool for assessing risk of bias (98) 
would be used to inform the screening of articles and to categorise them into several 
domains as either: low risk of bias, high risk of bias or unclear risk of bias. Differences in 
opinion would be resolved through discussion where possible, or through referral to a 
third author for consensus where necessary. 
 
The domains that are used to assess for risk of bias within studies are guided by those 
recommended in Cochrane’s risk of bias tool (99) and handbook (100): 
 
• Selection bias: evaluating the procedure used to generate the allocation 
sequence and whether the resulting groups would be sufficiently comparable. 
 
• Concealing allocation: Identifying and gauging the effectiveness of the method 
used to conceal allocation sequence and whether this would adequately prevent 
participants and/or study personnel from foreseeing the distribution of 




• Performance bias: examining what methods were used in blinding both the 
participant and study personnel from learning of any one intervention 
allocation, and whether these measures were reported to be effective. 
 
• Detection bias: assessing how the study personnel collecting outcome data were 
prevented from learning which patient was allocated which intervention, and 
whether these measures were reported to be effective. 
 
• Attrition bias: appraising the amount or nature of incompleteness of outcome 
data, e.g. due to factors such as participant drop-out and whether this is 
adequately reported and explained by researchers. Participant drop-out 
discrepancies may be picked up by comparing the number of participants who 
received any given intervention against the total number of participants initially 
randomised. 
 
• Reporting bias: determining the extent to which all outcomes of interest 
declared before the study began were subsequently measured and reported, 
and where reporting appears selective, whether researchers adequately and 
transparently detail reasons for this. 
 
• Other bias: any other issues deemed by the authors to increase a study’s risk of 
bias. 
 
The results of are then input to a “risk of bias” assessment tool within the Cochrane 
Collaboration’s Review Manager software (101). 
 
3.3.5.1 Publication Bias 
When a study produces negative results, this may influence researchers to decide not to 
proceed with publishing the trial (102). This can result in publication bias where the 
amount of published literature shows disproportionately positive results when compared 
to the actual overall wealth of evidence that has been collected, because these represent 
the most studies to go to publication. The implications for this in a systematic review are 
that results can be skewed positively compared to the truth, leading to the possible 
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inaccuracy of any conclusions and subsequent recommendations for both practice and 
research. 
 
3.3.5.2 Funnel plots 
To investigate the presence of publication bias, a funnel plot would be constructed 
including all studies selected for the review to visualise the distribution of studies from 
the line of no effect. This is a figure plotting any given trial’s estimate of the intervention 
effect against a measure of the study’s size or precision, such as the number of 
participants involved. The latter element is plotted on the vertical axis so that larger 
studies reside at the top of the graph. Because the precision of a study’s estimate of the 
treatment effect increases as the size of the study increases, it is expected that smaller 
studies will be scattered towards the bottom of a funnel plot. Therefore, the figure should 
resemble a relatively symmetrical inverted funnel if there is a lack of bias present 
amongst studies.  
 
An asymmetrical graph could be an indicator of publication bias, with the degree of 
asymmetry observed being related to the strength of the influence of bias. This is the case 
when smaller studies without statistically significant effects do not go to publication. It is 
important to note that some asymmetry could also be secondary to factors such as small 
sample sizes in trials or chance. Cochrane recommend that at least 10 trials should be 
included in a review for a funnel plot to discern meaningful results (103).  
 
3.3.6 Measures of treatment effect 
Dichotomous data, such as mortality rate for example, are analysed after first calculating 
effect sizes as odds ratios (OR) with 95% CIs. As it is common for study authors to use 
different measurement scales across different trials, standardised mean differences are 
calculated and presented with 95% CIs for continuous data (e.g. nutritional parameters). 
Time-to-event data are converted into hazard ratios (HR) with 95% CIs. 
 
Where similar outcomes are reported within several included studies, these are collated into 
meta-analyses to distinguish an overall treatment effect, and forest plots drawn up to 
illustrate the strength of effect. These plots allow visual inspection for indicators of both 





It is important to assess included studies for both clinical heterogeneity and methodological 
heterogeneity. As previously mentioned, examining forest plots for any obvious lack of 
overlap of the CIs or estimated treatment effects between studies can indicate the presence 
of heterogeneity. A statistical test used in Cochrane reviews and commonly included in a 
forest plot is the chi2 test which provides an indication of whether the differences between 
treatment effect estimates are down to more than random chance. When the chi2 statistic is 
large relative to its degree of freedom, this evidences the presence of heterogeneity beyond 
random variation. Because the test can be of low power where a small number of studies 
are concerned, a statistically significant result can support the presence of heterogeneity, 
but an output that is not 
 statistically significant cannot prove its absence (104). 
 
The I² statistical test can be performed to further estimate the level of heterogeneity 






) × 100% 
 
 
The following I2 output ranges (105) could be used to approximate the level of heterogeneity 
across studies: 
 
• 0-40%; may represent low-level heterogeneity 
• 30-60%; may represent moderate heterogeneity 
• 50-90% may represent substantial heterogeneity 
• 75-100% considerable heterogeneity 
 
The I2 result should also be interpreted in the context of the magnitude and direction of the 
treatment effects as well as the p value used for the original chi2 test (105). 
 
We did not propose to undertake any subgroup analyses initially. For example, as CFRD is 
more common in adults, we did not automatically consider subgroup analysis by age as this 
[47] 
 
could have introduced bias, e.g. older people with CF might have different perceived 
benefits. 
 
It was decided that, should it become apparent that there was substantial heterogeneity 
(identified through visual inspection of a funnel plot or through calculating I² values, 
denoted above) between studies, then we would consider removing relevant confounders 
for subgroup analyses such as sex or different models of CGM systems for example.  
 
If at least ten studies were included for meta-analysis in the review, these would have been 
performed through use of the formal test for subgroup differences in the Review Manager 5 
software (101). 
 
3.3.8 Meta-analysis and sensitivity analysis 
It was decided that a random-effects meta-analysis of studies deemed sufficiently similar for 
the results to be clinically important would be carried out. However, in the case of only one 
study being found to be eligible for inclusion in the review, it was agreed that it would be 
more appropriate to provide a narrative description of the single study's results. 
 
Sensitivity analysis is an assessment of how various sources of uncertainty may have 
affected the overall certainty of any subsequent meta-analyses performed. If one or more 
studies which met the criteria for inclusion in the review were deemed to have a high risk of 
bias in one or more of the GRADE framework (GRADE) domains (106), the authors would 
then deem it necessary to perform a sensitivity analysis. This would involve excluding these 
studies and performing another meta-analysis with the new data set before comparing the 











Records after duplicates removed 
(n = 1768) 
4. Results of the CFRD Cochrane systematic review 
4.1 Context of the results 
This work represents an original Cochrane systematic review in the process of being 
prepared for publication in collaboration with the Cochrane CFGD group. The basis of this 
study was guided by the “continuous glucose monitoring for monitoring cystic fibrosis 
related diabetes” topic on the group’s list of priority titles prior to authorising this review. An 
updated list of the group’s priority titles can be found on the Cochrane CFGD website (92). 
 





























Figure 5: A PRISMA (98) flow diagram detailing the stages at which different numbers of studies were excluded. 
Records identified through 
database searching 





























Additional records identified 
through other sources 
(n = 35) 
Records screened 
(n = 1768) 
Records excluded 
(n = 1757) 
Full-text articles assessed 
for eligibility 
(n = 11) 
Full-text articles excluded, 
with reasons 
(n = 11) 
Studies included in 
qualitative synthesis 
(n = 0) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
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4.2.1 Included studies 
As illustrated above, out of a total of 1768 studies, once duplicates were eliminated, there 
were found to be no completed RCT studies that appropriately fit our protocol’s criteria for 
inclusion in the review. The only study that did meet our criteria was a single RCT protocol 
(107) registered at clinicaltrials.gov (NCT03939065) that has not yet been undertaken, and 
thus, presented no data to be analysed for the review at this time. 
 
4.2.2 Ongoing studies 
From the data search process, we identified one RCT protocol, as mentioned above, 
registered at clinicaltrials.gov that could be eligible for inclusion in a future version of the 
Cochrane review (NCT03939065)(107). The RCT protocol, titled “Sensor Augmented Pump 
(SAP) Therapy for Inpatient Management”, is sponsored by the University of Colorado in 
collaboration with the Cystic Fibrosis Foundation and has an approximate start date of June 
2020 and estimated end date in February 2023 (NCT03939065). The pilot study plans to 
recruit 36 participants, between the ages of 8 and 25 years old, who are diagnosed with 
CFRD (based on ADA guidelines) and have been admitted for a pulmonary exacerbation.  
 
The trial will investigate the effects of CGM combined with insulin pump therapy (otherwise 
known as sensor augmented pump (SAP) therapy) on inpatients with CFRD, with the aim of 
optimising glycaemic control (NCT03939065). Participants will be randomised and assigned 
to one of two parallel treatment arms through study completion, for up to three weeks. 
Those allocated to the experimental arm will have their glucose levels monitored by CGM 
and receive their insulin dosing via the pump (NCT03939065). 
 
The control arm of the trial will consist of conventional diabetes management with multiple 
daily insulin injections (or an insulin pump where the patient was established on a pump in 
an outpatient setting) and CBG. Participants in the control arm will additionally wear a 
blinded CGM for outcome assessment. The outcomes they have stated they will report 
include differences in CGM percent time over 140 mg/dl, pulmonary function, circulatory 
inflammatory markers, weight, CBG level and beta-cell function (NCT03939065). 
 





4.2.3 Excluded studies 
From the original data search, 11 full text articles were excluded. Below, Table 1 outlines 
these studies and the reasons why they were removed from the study. 
 
Study number and title Study authors Reason(s) for exclusion 
1. “Cystic fibrosis-related 
diabetes in children--gaps in 
the evidence?” (108) 
Rana M, Munns CF, 
Selvadurai H, Donaghue KC, 
Craig ME. 
1. Non-RCT (Review of 
literature) 
2. CGM as a diagnostic tool 
2. “Update on diagnosis and 
monitoring of cystic fibrosis-
related diabetes mellitus 
(CFRD).” (109) 
Noronha RMD, Calliari LEP, 
Damaceno N, Muramatu LH, 
Monte O. 
1. Non-RCT (Review of 
literature) 
2. CGM as a diagnostic tool 
3. “A Practical Approach to 
Glucose Abnormalities in 
Cystic Fibrosis.” (110)  
Jones GC, Sainsbury CAR. 1. Non-RCT (Review of 
literature) 
2. CGM as a diagnostic tool 
4. “Screening for cystic 
fibrosis-related diabetes: a 
systematic review.” (57) 
Waugh N, Royle P, Craigie I, 
Ho V, Pandit L, Ewings P, et 
al. 
1. Non-RCT (Systematic 
review) 
2. CGM as a diagnostic tool 
5. “Cystic fibrosis-related 
diabetes: optimizing care 
with a multidisciplinary 
approach.” (111) 
Frost F, Dyce P, Ochota A, 
Pandya S, Clarke T, Walshaw 
MJ, et al. 
1. Non-RCT (Review of 
literature) 
 
6. “Cystic Fibrosis-Related 
Diabetes.” (37) 
Kayani K, Raihan M, Hasan 
M. 
1. Non-RCT (Review of 
literature) 
7. “Automated glycemic 
control with the bionic 
pancreas in cystic fibrosis-
related diabetes: A pilot 
study.” (112) 
Sherwood JS, Jafri RZ, 
Balliro CA, Russell SJ, 
Putman MS, Zheng H, et al. 
1. Wrong study design 
(crossover trial) 
8. “A service evaluation of 
the use of flash glucose 
monitoring in people with 
Guilbert L, Arregui-Fresneda 
I, Daniels T, Holt RIG. 





diabetes (CFRD).” (113) 
9. “294 Exploring the utility 
of continuous glucose 
monitoring (CGMS) for 
cystic fibrosis related 
diabetes (CFRD).” (95) 
Jackson VM, Dyce P, 
Walshaw MJ. 
1. Non-RCT (retrospective 
observational study) 
10. “336 The impact of 
continuous glucose 
monitoring on HbA1c in 
patients with cystic fibrosis 
related diabetes.” (94) 
Stackhouse CA, Floto R, 
Haworth CS, Shafi NT, 
Buczak V, Johnson CM, et al. 
1. Non-RCT (single 
assignment study) 
11. “Validation of 
continuous glucose 
monitoring in children and 
adolescents with cystic 
fibrosis: a prospective 
cohort study.” (65) 
O'Riordan SM, Hindmarsh P, 
Hill NR, Matthews DR, 
George S, Greally P, et al. 
1. Non-RCT (cohort study) 
2. This study validated CGM 
for use in pwCFRD but made 
no link between the use of 
CGM and management of 
CFRD 
Table 2: Table of articles excluded at the full text stage. 
Four studies were excluded because they focussed on CGM as a method of diagnosing or 
screening for CFRD rather than monitoring the disease, three of which related to (non-
systematic) reviews of established literature (108-110).  
 
The first of which, published in 2010, lists CGM as one method of screening for and 
diagnosing CFRD, noting that hyperglycaemic peaks have been demonstrated via CGM in 
pwCF who have otherwise normal OGTTs and therefore CGM can detect hyperglycaemia 
earlier than OGTTs (108). In the same paper, Rana et al. describe a CGM readings of 
>7.8mmol/l for ≥4.5% of the time as being “associated with declining weight SD scores and 
lung function in the preceding year”(108). The authors go on to suggest that CGM could aid 
diagnosis of CFRD when used in conjunction with the OGTT and clinical judgement.  
 
The second paper, by Noronha et al., made only one reference to the use of CGM which was 
in the context of diagnosing ‘indeterminate’ glycaemia which they described as “post-
[52] 
 
prandial hyperglycaemia detected by continuous glucose monitoring (CGM), in the absence 
of symptoms suggestive of diabetes”(109). 
 
In the third paper, Jones et al. also suggest the use of CGM as an adjunct to the OGTT to 
evaluate glucose at 1 hour post-glucose load as isolated hyperglycaemia at this point is 
known to affect lung function in CFRD (110). 
 
The fourth study excluded, for investigating the diagnostic capabilities rather than the 
therapeutic monitoring usage of CGM, was an extensive systematic review of four major 
databases by Waugh et al (2012) which examined the methods of screening for CFRD and 
the effectiveness of available treatments (57). The authors suggested that because CGM is 
better at detecting hyperglycaemia, it may be the “best screening test” and become the gold 
standard for diagnosis in the future, with a caveat that further evidence on the topic is still 
required. The paper explains that trials investigating the effects of starting insulin at 
different stages of hyperglycaemia, beginning with post-prandial hyperglycaemia diagnosed 
through tests such as CGM. Waugh et al also wrote that further evidence on the “relative 
merits of the 1-hour GCT, CGMSs and serial profiles is required, with the aim being to detect 
any hyperglycaemia >8mmol/l” (57). 
 
Another reference (111), written by Frost et al. (2019), was excluded as it consisted of a 
literature review rather than an RCT. The paper describes the integration of CGM data 
feedback with the efforts of the various CF MDT members, to devise an appropriate plan of 
care for pwCFRD. They hypothesise that, in the future, a CGM-informed tripartite approach 
to devising treatment plans by the advanced nurse practitioner, CF dietician and the pwCF 
themselves may become the ‘gold standard’ (111). 
 
Reference number 6 in Table 1 (37) was also excluded due to being literature review. The 
2018 paper by Kayani et al. comments on the 2016 paper by Bolinder et al. (114), which 
established the utility of CGM in the monitoring and management of T1DM, and 
extrapolated that CGM may therefore be a feasible alternative to CBG in CFRD. Said paper by 
Bolinder et al. presented no direct evidence to support this use of CGM in pwCFRD.  
 
A pilot study (112), ruled out due to its crossover design and published this year by 
Sherwood et al, investigated the use of a ‘bihormonal bionic pancreas’, originally designed 
[53] 
 
for people with T1DM, in 3 pwCFRD. The device used CGMS guided monitoring of glucose 
levels to automate administration of insulin and glucagon accordingly. The second arm of 
the study involved an insulin-only setting of the same device, also linked to CGM data, 
whereas the third arm consisted of usual care. In people with T1DM, both interventions had 
previously been shown to reduce mean CGM glucose reading, with the bihormonal setting 
also reducing time spent in hypoglycaemic glucose ranges (112). Both configurations of the 
device lowered participants’ mean glucose with minimal hypoglycaemia; the authors 
concluded that their results warranted further investigation of automated glucose regulation 
technology in pwCFRD (112).  
 
Three studies (94, 95, 113) that focussed entirely, or in part, on the outcomes of using CGM 
guided treatment of CFRD were removed at the full-text stage due to having study designs 
that were incompatible with our criteria. This included a retrospective case-notes review, 
published in 2018 by Guilbert et al., of 145 pwCFRD, 16 of which had their treatment 
modified secondary to the CGM data and “led to clinical changes in a significant number of 
patients” (113).  
 
The second of these three to be excluded, study 9 from Table 1 by Jackson et al., was a 
review of the reasons why 99 unrandomised instances of CGM in 85 people were carried out 
in a CFRD clinic, alongside patients’ clinical outcomes 3-6 months after (95). Fifty-five 
patients received CGM for “ongoing management”. The authors describe CGM as a useful 
educational tool to help pwCFRD and their carers to better understand their condition, as 
well as a “useful tool to aid the management of people with CF who already have [CFRD]” as 
the FEV1 improved in 74% of those who had their treatment adjusted in response to CGM 
data, whereas 60% improved their weight in response (95). 
 
The third article was about a single assignment study, by Stackhouse et al., of 11 pwCFRD 
who were failing to provide CBG data and was excluded since it did not follow an RCT design 
(94). Participants’ insulin regimens were altered based on 3-day blinded CGM and followed 
up at 3, 6 and 12 months. This led to a “significant drop in HbA1c that was maintained for at 
least 12 months”, leading the authors to conclude that CGM may be useful where collecting 




A final reference excluded at the full text stage referred to a cohort study aiming to validate 
the reliability, reproducibility and repeatability of CGM, in comparison to OGTT, to assess 
hyperglycaemia in 102 children and adolescents with CF (65). O’Riordan et al. concluded that 
CGM is a valid measure of glycaemia in children and adolescents with CF. Because this trial 
made no link between using collected CGM data and altering CFRD treatment, and because 
it was not an RCT study design, it was removed from the data collection process. 
 
In summary, despite conducting an exhaustive literature review spanning five major 
databases, we have not identified any data from randomised controlled trials that have 
evaluated the impact of CGMS on the well-being of pwCF with CFRD. 
 
4.3 Assessing risk of bias and the quality of evidence 
Only one study was found to be potentially eligible for inclusion in this systematic review. 
However, as it relates to a protocol of a study yet to begin, the study was excluded at the 
screening stage and the data currently available is insufficient to accurately assess what the 
risk of bias would be. 
 
If it had been the case that there had been studies included in the review, they would have 
been independently examined (by AT and AM) to determine the risk of bias present in each 
study as well as grade trials according to the GRADE criteria, which are outlined in the next 
section. Below is an example of how the results of the risk of bias assessments would be 
tabulated to allow a simple visual comparison of the relative strengths and weaknesses 
across studies; with green representing a low risk of bias, yellow signifying an unclear risk of 
































Study X        
Study Y        
Table 3: Example of a summary table of risk of bias outcomes following assessment of studies included in a 
hypothetical Cochrane review. 
[55] 
 
A figure such as Table 1 would also be associated with a further separate table for each 
included study. These additional tables would outline the specific reasons why a given study 
would be assessed as having a particular level of bias in each stated category, an example of 
which is demonstrated in Table 2 following on from fictional “Study X” in Table 1. 
 




Low risk E.g. An independent party 
generates a random 




Unclear risk E.g. Method of allocation 
concealment not stated. 
Participant / personnel 
blinding 
(performance bias) 
Low risk E.g. Study personnel and 
participants were 
blinded to treatments 
Packaging and medications 
taken by participants were 
visually identical. 
Blinding of outcome 
assessment  
(detection bias) 
Unclear risk E.g. Insufficient information 
supplied on the methods 
used to blind assessors 
and/or the effectiveness of 
this in practice. 
Incomplete outcome data  
(attrition bias) 
 
Low risk E.g. All participants who 
were randomised were 
accounted for. 
Selective reporting  
(reporting bias) 
 
High risk E.g. Multiple outcomes of 
interest stated in the 
protocol and recorded in 
the trial have not been 







Low risk E.g. The authors did not 
have any additional 
concerns 
Table 4: Example of a hypothetical risk of bias assessment explanation table for “Study X”. 
4.3.1 The GRADE framework 
The GRADE framework was developed by the GRADE Working Group which is made up of a 
variety of health care personnel including clinicians, researchers, guideline developers and 
public health officers (106). The framework aims to provide a consistent, transparent criteria 
to assess the quality of evidence and the strength of guidelines by which healthcare 
decisions are made (106), and is endorsed by over 100 organisations globally (115). The 
meanings of the four levels of evidence scoring are demonstrated below. 
 
GRADE score Meaning of the score 
High certainty One can be very confident that the true effect 
lies close to the estimate of the effect. 
Moderate certainty The true effect and the estimate are likely to be 
close, but there is a possibility that they are 
substantially different. 
Low certainty Confidence in the effect estimate is limited, the 
true effect and the estimate may be 
substantially different. 
Very low certainty There is very little confidence in the findings: 
the true effect is likely to be substantially 
different from the estimate. 
Table 5: The four levels of evidence in the GRADE framework 
 
RCTs, as discussed, are often held as the gold standard for producing low-bias evidence (74) 
and as such, the GRADE framework starts with RCTs graded at ‘high certainty’ and non-
randomised studies at ‘low certainty’ (106). 
 
In the case of meta-analysis or narrative synthesis, reviewing certain elements of studies can 
raise or lower the certainty of the conclusions drawn by that study. Factors that may lower 
the GRADE score of a study include (115): 
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• Overall risk of bias across studies that contribute data for an outcome. 
 
• Inconsistency: where there are widely differing estimates of effect, for example, 
owing to heterogeneity. 
 
• Indirectness: where studies do not directly answer or apply to the review question 
 
• Imprecision: Where there are few participants or events across studies, or 
particularly wide confidence intervals. As a rule of thumb, having less than 400 
people or events across studies warrants consideration of a GRADE level being 
dropped (106). 
 
• Publication bias: to consider dropping a GRADE level due to publication bias, there 
must be strong suspicion of selective publication of studies or outcomes, and this 
can only result in a maximum drop of one certainty level. 
 
Where there are no concerns about the above aspects, the GRADE level should not be rated 
down, though serious concerns about any domain listed can cause a rating to drop one level, 
or two levels where there are very serious concerns about these elements (115). 
 
On the other hand, in rare circumstances, the level of GRADE certainty can be raised, 
including in the case of a dose-response gradient or where a large relative effect is 
demonstrated (rated up by two levels where this is ≥5, or by one where it is <5 but >2)(106). 
 
4.4 Effects of interventions 
Only one paper was identified as having potential for inclusion in this review. As it is an 
ongoing trial with no current results, it was excluded and therefore no studies with outcome 
data have been included for review. This means that the effect of using CGMS to guide 
insulin therapy modification in the context of CFRD currently remains undetermined. 
 
4.5 Summary of results 
This Cochrane review identified no current RCT data, evaluating the utility of CGMS in the 
context of CFRD, out of 1768 initial results. One registered protocol for an RCT was identified 
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as meeting the criteria for inclusion, however, they have not yet collected any data. Once 
available, this study will be fully assessed for quality and data included if appropriate. 
 
4.6 Overall completeness and applicability of evidence 
We identified an absolute lack of relevant evidence to answer the review question, 
regarding the effect of using CGM to titrate insulin regimes in pwCFRD. Most studies 
examining the use of this intervention are in people with T1DM (87), including a Cochrane 
review (79, 85, 87), but there remains no evidence about its applicability for pwCFRD in this 
context.  
 
4.7 Potential biases in the review process 
Cochrane methodology was adhered to minimise the risk of bias throughout each step of the 
review. This included producing a protocol to be published after peer review and performing 
a comprehensive search of the Cochrane CFGD Group’s register of CF related trials, both 
complete and ongoing.  
 
The total resulting studies of the literature searches were independently assessed by 
authors AT and AM using the predetermined inclusion criteria outlined in the protocol, 
before extracting data and grading the risk of bias in included studies would be done. These 
steps were all undertaken in a parallel fashion by AT and AM, with any discrepancies then 
being resolved through joint discussion, or mediation by a third author where necessary. 
Analysis of the data would then have been performed using Review Manager software (101). 
 
The authors are aware of the possibility that our search may have retrieved fewer records 
than we intended due to the inaccessibility of the WHO ICTRP. However, this database is 
regularly searched for RCTs which are then added to the Cochrane CENTRAL trials 
register(116) which was included as part of our search strategy,  making it less likely that 
relevant trials have been missed.  
 
This situation will continue to be monitored and, if the circumstances change, the database 




4.8 Agreements and disagreements with other studies or reviews 
There is a published protocol for a ‘diagnostic-test accuracy’ style Cochrane review 
examining continuous glucose monitoring systems for the diagnosis of cystic fibrosis-related 
diabetes (91). We are not aware of any published systematic reviews of RCTs evaluating the 
impact of CGM on the management of, and subsequent outcomes observed in people with 
CFRD.  
 
4.9 Creating a framework for future studies  
Having demonstrated the lack of research currently available to determine the impact of 
CGM on the management of pwCFRD, a collaborative discussion was held to determine how 
future studies could best go about producing a robust evidence base on this topic. This 
included both an independent chair and the author group for this review which consists of; a 
CFRD specialist Advanced Nurse Practitioner, a respiratory consultant, a respiratory 
medicine trainee doctor, and a medical student/postgraduate researcher. The final member 
of the team, another medical student, was unavailable for the initial meeting. 
 
Our aim was to determine a framework for research on this topic to expand the current 
knowledge base. Details of the resulting recommended study characteristics are included in 

















The main body of this work centres around an original Cochrane systematic review designed 
to investigate the impact of continuous glucose monitoring systems on the lives of pwCFRD. 
They were specifically investigated with reference to how data collected through CGMS 
leading to alterations to a person’s insulin regime, e.g. dosage, type of insulin, number of 
doses; may affect their outcomes, both clinical and non-clinical. This was compared to 
outcomes observed following insulin titration secondary to traditional therapy i.e. guided by 
CBG or HbA1C.  
 
As CFRD is becoming more prevalent due to factors such as the improving life expectancy of 
pwCF; the impact of CFRD on peoples’ lives is of increasing importance, as is research into 
ways to help alleviate treatment and disease burden for individuals. As part of this, it is 
imperative to ensure that these new technologies are properly evaluated and information 
about their effectiveness is kept up to date. Creating and maintaining a sturdy body of 
evidence supports the decision-making of policy makers, clinicians, and patients alike. 
 
CGMS is an expensive resource, particularly in comparison to the use of the CBG method 
(117) and cost-effectiveness is an important consideration for policy makers. More research 
is needed to determine a clear evidence base upon which to support widespread 
implementation of CGMS for the management of CFRD if it is shown to be appropriate and 
economically feasible to do so.  
 
This could be especially pertinent for pwCFRD in countries such as the USA where personal 
medical costs and insurance coverage may present further barriers to the availability and 
uptake of new interventions, even when they are shown to be beneficial (87). This issue is 
relevant globally; a robust evidence base encourages funding and allows clinicians to get 
access to these treatments for their patients. 
 
5.1 Summary of findings 
The results of this study indicate that the evidence currently available is insufficient to 
determine the impact of continuous glucose monitoring on the management of people with 




Throughout the data collection and literature review performed for our Cochrane review, 
there was found to be a growing number of studies aiming to evaluate the utility of CGM as 
a diagnostic test for CFRD and/or deciding when to first initiate insulin therapy (56, 64, 65, 
91), yet recommendations across guidelines have remained relatively nonspecific (14). There 
was limited literature relevant to the use of CGM as an aid to managing the treatment 
regimens of pwCFRD who already take insulin as demonstrated by the results of our 
Cochrane review.   
 
One reason for this is the lack of clinical trial data on the best approach for treatment of 
CFRD with no clear consensus on which type, frequency or mode of delivery of insulin is best 
for pwCFRD (28, 59). A 2016 Cochrane review, comparing different types of long or short 
acting insulin as well as oral hypoglycaemic agents for the treatment of CFRD, acknowledged 
that insulin therapy is the most widely used therapy for CFRD, as endorsed by the Cystic 
Fibrosis Foundation (118, 119). The same review found no significant conclusive evidence 
that any one of these treatments conveyed more benefit to pwCFRD than another in terms 
of stabilising hyperglycaemia and improving outcomes (118).  
 
This uncertainty is echoed within the ADA clinical care guidelines for CFRD where they 
endorse the use of clinical judgement to discern the best regimen for individual patients, 
and acknowledge the lack of evidence surrounding comparative superiority of specific insulin 
regimens in CFRD (28). There is a lack of consistency in how clinicians diagnose CFRD, when 
insulin treatment should be initiated, and what regimen is best to treat pwCFRD. These 
factors likely contribute to issues for researchers designing studies to evaluate the 
effectiveness of types of glycaemic data collection, such as CGM, upon which these many 
decisions are usually based. 
 
In the context of this Cochrane review, CGM was not being evaluated as a stand-alone test, 
but rather as an adjunct to treatment. To some degree, CGM can only impact clinical 
outcomes when linked to a defined and proven treatment protocol stipulating how the 
patient should be treated for any given excursion in blood glucose. Additionally, real-time 
CGM has potential to act as an intervention to help educate pwCFRD on how their treatment 
affects their glucose levels. There is potential for this intervention to empower pwCFRD to 
understand their condition better and take more control over how to respond to trends in 
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glucose rather than just individual CBG glucose readings, as has been demonstrated in other 
diabetic populations (120). 
 
Conversely, there is concern that this aspect of real-time CGM could negatively impact 
pwCFRD, as having nearly 24-hour information on their glucose levels could present a 
burden. Through stakeholder engagement it was made clear that there were concerns that 
the almost constant knowledge of the direction of glucose trends could trigger some 
pwCFRD to try to ‘chase’ the numbers, when permanently maintaining normal glucose levels 
is unrealistic and associated with a risk of hypoglycaemia (121). It is important that the 
potential distress of this continuous stream of data is considered and evaluated; particularly 
for pwCFRD, who already face a significant burden of treatment and reduced quality of life 
compared to their non-diabetic counterparts. As such, it is important that further research 
examines the complex psychological implications of CGM use to ensure that it is 
implemented in a way that is most beneficial to pwCF. 
 
5.1.1 Available evidence 
Though it was unfortunate that our protocol’s rigidity meant our searches did not find any 
studies eligible for inclusion in the review, some of the non-RCT studies that were excluded 
at the ‘full text’ stage, outlined in chapter 4.2.3, did add important knowledge pertaining to 
CFRD.  
 
Waugh et al. 
Although it focussed on the diagnostic capabilities rather than the therapeutic monitoring 
usage of CGM, the extensive systematic review by Waugh et al also reviewed the 
effectiveness of available treatments for CFRD (57). While including a caveat that further 
evidence on the topic is still required, there was a suggestion that CGM is better at detecting 
hyperglycaemia in a diagnostic context than other forms of glucose monitoring, i.e. CBG and 
OGTT (which is assessed via CBG). This reflects that CGM could be more capable of 
identifying abnormal peaks than CBG in the context of monitoring in pwCF who already have 







Sherwood et al. 
Ruled out due to its crossover design, Sherwood’s paper investigating the use of CGM-driven 
automated glucose regulating technology in 3 pwCFRD. While this was a small pilot study, 
the results were exciting given that the device lowered participants’ mean glucose without 
triggering any major hypoglycaemia and was a treatment that participants found acceptable 
(112). Despite this, the study needs to be interpreted with caution given the small sample 
size and crossover nature of the trial and thus the potential for the effects of one 
intervention having interfered with the results of the next intervention. Another concern is 
that while the authors were examining a version of CGM-led insulin therapy, their focus was 
directed at the use of sensor augmented pump therapy rather than the benefit of CGM 
specifically. Still, further studies in this area, such as trial denoted by the protocol described 
in section 4.2.2 (107), have the potential to expand our current knowledge base on CGM 
directed management of CFRD. 
 
Guilbert et al. 
This study focussed on the clinical utility of ‘flash’ CGM, with 145 pwCFRD involved. Sixteen 
people had CGM to change/affirm treatment and six people had CGM to support 
engagement with treatment. The paper claims that changes made secondary to CGM “led to 
clinical changes in a significant number of patients”, however the only format available for 
this retrospective case-notes review was a journal abstract, limiting the utility of its data 
(113). 
 
Jackson et al. 
This conference abstract reviewed the reasons why 99 unrandomised instances of CGM in 
85 people were carried out in a CFRD clinic (95). The authors describe CGM as a useful 
educational tool to help pwCFRD and their carers to better understand their condition, as 
well as a “useful tool to aid the management of people with CF who already have [CFRD]” 
(95). Despite this, Jackson et al. do not provide the criteria by which they determined this, 
nor statistical data to back up the otherwise anecdotal evidence. Upon contacting the 
authors for further information, a poster version of the data was received with no further 






Stackhouse et al. 
Another article available only as an abstract, this work described how 11 pwCFRD who were 
failing to provide CBG data had their insulin regimens altered based on an isolated 3-day 
blinded CGM (94). The significant drop in HbA1c that was maintained for at least 12 months 
in these patients is a positive finding that could indicate the utility of CGM-led insulin 
therapy in pwCFRD who are needle phobic or may struggle to take CBG readings as often as 
recommended or at all (94). The concept that one 3 day period of CGM could make such a 
substantial and sustained difference to measures of hyperglycaemia raises the question of 
how daily, or almost daily, CGM use could impact the management of pwCFRD. It is 
recognised that this study also had quite a small sample size and that, again, further 
evidence is required on the topic. 
 
O’Riordan et al. 
Although this cohort study by O’Riordan made no link between using collected CGM data 
and altering CFRD treatment, the validation of the reliability, reproducibility and 
repeatability of CGM in assessing hyperglycaemia pwCF (65) is incredibly important for the 
development of further research on this topic. Proving that CGM can be used to accurately 
reflect blood glucose is a key element in being able to perform trials on CGM data-led 
management alterations. 
 
5.2 Development of outcome measures for this review 
The James Lind Alliance (JLA) engages with groups of stakeholders to explore and prioritise 
the uncertainties and unanswered questions that surround a specific area of health, such as 
CF. These groups are called priority setting partnerships (PSPs) and include patients, carers 
and health and social care professionals whose perspectives are consulted to compile the 
top 10 priorities list (the full list of which can be found in the appendix)(90). The goal of this 
process is to steer researchers and allocation of funding in the direction of addressing the 
issues which are directly relevant and likely to be of the most benefit to both people living 
with an illness and those involved with caring for someone who does. The PSP for pwCF 
established that the number one priority is determining effective ways of simplifying their 
large treatment burden (89, 90). 
 
These priority areas were considered during the outcome development process for this 
review, in particular; investigating ways of simplifying the treatment burden and helping to 
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delay or prevent the progression of lung disease in early life in people with CF (90). 
Consequently, this resulted in the inclusion of both percentage change in FEV1 (as a marker 
of lung disease) and the burden of treatment experienced by pwCFRD as outcomes of 
interest to help address these issues. 
 
To further ascertain what our main outcomes of interest would be for this review; research 
was also conducted into the outcomes deemed most important by pwCFRD and their 
families as well as the clinicians involved in their care. Initially, clinicians from the CF team in 
Alder Hey Children’s Hospital were consulted regarding what parameters they felt to be 
most pertinent to the ongoing assessment of CFRD. These were largely clinically measured 
outcomes such as lung function and CFRD (or CFRD treatment) related adverse effects.  
 
As part of the stakeholder engagement process, author AT conducted semi-structured 
interviews with pwCFRD and their families/carers; exploring what aspects of their treatment 
mattered the most to them. Interestingly, this highlighted the impact of more personal 
factors on pwCFRD, especially the burden of treatment and quality of life they experience. 
Those consulted also emphasised nutritional parameters, especially weight, as a key element 
of their own monitoring of their conditions, both CF and CFRD. They often linked 
maintenance of body mass with better lung function, a lower rate of respiratory infections 
and being an indicator that their diabetes was under control, as backed up by the research 
data detailed in the first chapter of this thesis (7, 11, 14, 15, 19-22, 43). This helped shift our 
focus to outcomes that are not strictly clinically imperative, but that have significant impact 
on the lives and wellbeing of pwCFRD. 
 
5.3 Limitations 
This work represents an extensive literature review. However, as touched upon in the 
methodology chapter, the advent of the COVID-19 pandemic impacted elements of this 
work.  
 
Firstly, the publication of the protocol was delayed due to the nationwide disruption caused 
by lockdown and the associated reduction in staffing and an increase in workload across 




We were also unable to access the WHO ICTRP due to COVID-19; however, the Cochrane 
CENTRAL clinical trials registry, which is regularly updated with relevant records for RCTs or 
quasi-RCTs listed in the ICTRP, was searched for the purposes of this systematic review.  
 
These issues first occurred during the initial data collection phase of the Cochrane review, 
mandating that this database was omitted for the purposes of this thesis due to time 
constraints. Despite this, we will still endeavour to incorporate search results from the 
original ICTRP into the final systematic review before submission for publication. 
 
5.4 Implications for clinical practice 
No randomised controlled trials were identified to evaluate the impact of continuous 
glucose monitoring systems on the management of people diagnosed with cystic fibrosis 
related diabetes. As a result, it is not currently possible to draw reliable conclusions on the 
potential benefits or harms of CGMS-guided insulin regimes in pwCFRD. 
 
In people with T1DM, Bolinder et al. have shown that CGM reduced hypoglycaemia and the 
number of CBGs required per day, making it a plausible and highly acceptable alternative to 
CBGs in this population (114). CFRD has a distinct pathophysiology to T1DM, thus caution 
should be taken in extrapolating the observed effects of CGM on the management of people 
with T1DM to the presumed impact the technology will have on management of pwCFRD. 
 
While the lack of research surrounding the impact of CGM in pwCFRD means that there is no 
evidence of potential benefits of the intervention, it equally has not explored any possible 
associated adverse effects. This means that any current use of CGM in the context of CFRD is 
likely based on evidence that is anecdotal (111) or extrapolated from research pertaining to 
its use in other forms of diabetes.  
 
There is a need to accurately and transparently evaluate any adverse effects of using CGM 
both in general and in pwCFRD (122). For example, if the CGMS malfunctions or the 
algorithms incorrectly process the data, inappropriate modifications to insulin dosages could 
be made resulting in clinically significant adverse events (62). Individuals using closed loop 
SAP therapy are particularly at risk of this (62, 122). Use of CGMS is known to be associated 
with skin-related issues, usually localised to the sensor insertion site, such as contact 




As discussed, there is currently no evidence to support the costly implementation of CGM to 
manage CFRD, although there are indications that CGMS are already being used in this 
context in some countries, such as the United Kingdom (111).  
 
5.5 Implications for research 
As discussed, there are currently no data available on the impact of CGM on the 
management of pwCFRD. Absence of evidence is not necessarily evidence of absence of 
effect, and therefore it is hoped that publication of this review will raise the profile of the 
question at hand and generate sufficient research to provide improve the evidence base. 
 
In addition to assessing the technological advancement of glucose regulating therapies, in 
building upon the stakeholder engagement that was undertaken for this review, it is 
apparent that there is a need for further qualitative research to be performed to examine 
the qualitative aspects of the experience of pwCFRD and to further ascertain what outcomes 
truly make the most difference to their lives. Large scale qualitative studies carried out in a 
similar fashion to the JLA’s PSPs (90) where as many stakeholders as possible are consulted 
until no new themes appear, can help ensure that no key concerns are overlooked. This kind 
of study could be greatly beneficial in guiding future trials in the direction of assessing 
appropriate outcomes to help elicit which therapies maximise benefit and minimise harm to 
pwCFRD. 
 
As technology changes and is updated rapidly, there is a need for research to stay abreast of 
these developments, to ensure that the available evidence stays relevant and robust. The 
Cochrane Collaboration policy is that reviews should be updated every two years or less, or a 
commentary explaining why this has not been the case should be included (59). Once the 
aforementioned included RCT protocol (107) is completed, it may be appropriate to conduct 
an update of this review. Future versions of this review could also explore a cost-benefit 
analysis of CGM versus traditional methods of CFRD monitoring such as CBGs. 
 
CFRD is a complex condition that mandates the addition of treatments such as insulin 
schedules on top of all of the therapies already involved in managing CF on a daily basis.  
Research to explore ways to reduce the burden of treatment experienced by pwCF and 
pwCFRD is imperative (90). Investigation into CGM in this context should be a priority as it 
[68] 
 
potentially may offer an alternative to the burden of multiple daily uncomfortable CBGs, or 
help prevent increasing burden of treatment and burden of disease secondary to CFRD 
specific complications through its theoretical potential to improve long term glycaemic 
control (79). For these reasons, further research in this area could also help address the JLA’s 
sixth research priority in evaluating CGM as a technology with the potential to help motivate 
and support pwCFRD to improve and sustain adherence to their treatments (90). 
 
In some cases, CGM is already in use within clinical practice settings (37), it has been 
implemented by some specialist advanced nurse practitioners in the context of CFRD for 
ongoing monitoring as well as instigation and titration of insulin therapy (37, 111). This 
further highlights the need for comprehensive investigation into the benefits and harms this 
may confer to pwCFRD in order to adequately support an evidence-based medical approach 
and help patients, clinicians and other stakeholders make informed decisions regarding the 
use of CGM for CFRD. With this in mind, the authors conducting this review propose a 
potential trial design below to address the review question.  
 
5.5.1 Discussion of future trial formats 
The recommended design would consist of a randomised controlled trial including people 
with a formal diagnosis of CFRD, of at least 6 to 8 years of age. This approximate age was 
suggested due to the cooperation required from patients in the measurement of outcomes 
such as FEV1 (124), as the validity of the outcomes is paramount whilst still tracking from a 
relatively early stage of the condition (2). We would hope this lower age limit would help 
prevent unnecessary exclusion of children who have been appropriately diagnosed before 
the age of ten; the recommended age for annual screening (125). It was thought that a 
registry-based study with a specific strategy of monitoring and associated management 
would be necessary to yield more accurate results in terms of the effect that CGM has on 
the management itself. It would also be ideal for a trial to have a lengthy follow-up period 
for the assessment of long-term outcomes such as lung function and microvascular disease 
as these changes can happen slowly over time (31), though it is recognised that the 
practicality of monitoring participants for up to 10-15 years in order to assess such outcomes 
may be limited. For this reason, if it were to be shown that CGMS could significantly reduce 
hyperglycaemia, it may be feasible to consider this as a surrogate outcome for some longer-
term outcomes. If hyperglycaemia can be consistently controlled, it is likely that the 
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incidence of CFRD complications, such as microvascular disease, will also be reduced. The 
other outcomes of interest would consist primarily of those listed in this review.   
 
Such a study would focus on the impact of using CGMS-collected data to make adjustments 
to an individuals CFRD treatment, such as insulin dosage or frequency as discussed in this 
work. Alternatively, a future study could seek to find whether manipulating the diet of 
pwCFRD can prevent the significant peaks and troughs often picked up via CGMS data 
collection. If this could be shown to help stabilise control of blood sugars or even reduce the 
need for insulin, this could potentially have a significant positive impact on the treatment 
burden of pwCFRD as well as improving long term outcomes by reducing both hypo- and 
hyperglycaemia. 
 
Previous studies of CGM technology have demonstrated the potential for variability in effect 
across different diabetic populations (79), highlighting the need for future research to 
encompass investigating the impact of CGM on different demographics within the 
population of pwCFRD i.e. across different age groups and during pregnancy. 
 
In terms of prospective study designs, it was considered that participants could be 
randomised to a two or three-armed approach. The various possible combinations in each 
case are detailed below in Tables 4 and 5. 
 
Intervention Arm Control Arm 
Real time CGM (i.e. FreeStyle Libre) CBG 
Blinded CGM CBG 
Real time CGM  Blinded CGM 
Table 6: Possible interventions arms for a two-armed RCT investigating the use of CGM for CFRD. 
Initially, it could be preferable to investigate either real-time or retrospective CGM 
compared to a control group, using CBG. This could help to first establish the impact of these 
devices under the umbrella of CGMSs as an intervention for CFRD compared to current 
standard treatment (28), before conducting research into any merits and/or issues the two 





Arm 1 Arm 2 Arm 3 
CBG Real-time CGM Blinded CGM 
(with CBG QDS) 
Table 7: Possible interventions arms for a three-armed RCT investigating the use of CGM for CFRD. 
CGMSs can also be used ‘continuously’, i.e. daily or almost daily, versus ‘intermittently’, for 
example in the case of pwCFRD who normally use the CBG method to monitor their glucose 
levels but undergo a period of CGM to support changes to their diabetes treatment. These 
constitute two related but separate implementations of CGMS, and research into the impact 
of both applications on the monitoring and management of pwCFRD is warranted. Still, it is 
perhaps worth noting that in non-CF diabetic patients, to get the most benefit from CGM, 
the ADA recommends that the technology is used “as close to daily as possible”, with CGMSs 
being scanned at least every 8 hours (62). In addition to this, a Cochrane review on CGM in 
people with T1DM described indications that higher compliance with wearing CGMSs 
improves markers of hyperglycaemia to a greater extent (79).  
 
Taking these findings into account, it could be reasonable to prioritise the ‘continuous’ 
application of CGM when devising future studies. For example, in a population of pwCFRD, 
‘continuous’ CGMS could be compared with another form of CGM or another method of 
blood sugar monitoring such as CBG. In pursuit of identifying the impact of CGMS on 
pwCFRD, the resulting short and long term outcomes associated with this could then be 
examined, including quality of life, lung function and adverse effects as previously described 
in this work. 
 
5.5.2 Limitations when devising studies 
A confounding issue noted surrounding the suggested study designs is that where 
participants might be randomised to a blinded CGM arm, CBG could be required up to QDS 
for calibration of the device (126). This is a complex limitation as even if this calibration was 
not necessary, the use of a blinded CGM with no real-time data (from CGM or CBG)  would 
still present an ethical issue of leaving a patient who is taking insulin without means of 





The inability to completely mask participants and study personnel from the allocated 
intervention, for example due to the nature of CGM sensors needing to be inserted into the 
skin, is a recognised issue across glucose technology studies to which there is no practical 
resolution (114, 127). The potentially increased risk of bias associated with this problem 
should be kept in mind and care must be taken when interpreting the findings of such 
studies, with both the strength and validity of the outcomes as well as the duration of such a 






























This is the first systematic review to examine the impact of continuous glucose monitoring 
on the management of people with cystic fibrosis-related diabetes. The outcomes selected 
for the review were determined following stakeholder engagement with a variety of 
clinicians and health care professionals, as well as pwCFRD and their families. The selected 
outcomes focused on identifying meaningful differences to the lives and wellbeing of 
pwCFRD, not just surrogate clinical parameters. 
 
Despite a comprehensive literature search of five major databases, no trials were identified 
to evaluate the effect of using CGM to monitor and manage CFRD. This search identified one 
protocol for an RCT, scheduled to begin recruiting participants later this year, as being 
potentially eligible for inclusion in a future update of this review (107). 
 
This review highlights the need for a significant amount of research in this area to address 
the current gap in knowledge. As a result, a proposed future framework for clinical trials has 
been produced; investigative studies on this topic would ideally follow an RCT design and 
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Blank summary of findings table for studies included in the Cochrane systematic 
review 
Intervention A compared with placebo/intervention B for condition 
Patient or population: Patients with Cystic Fibrosis Related Diabetes 
Settings: 
Intervention: CGMS-directed insulin therapy 
Comparison: standard insulin therapy (e.g. CBG-led) 
Outcomes Illustrative comparative 
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Time in range 
(proportion of 
time within a 
normal blood 
sugar profile)  
Scale: complete 
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Follow up: up to x 
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Abbreviations: CGMS (continuous glucose monitoring systems), CFRD (cystic fibrosis related 
diabetes) 
GRADE Working Group grades of evidence 
High certainty: One can be very confident that the true effect lies close to the estimate of the 
effect. 
Moderate certainty: The true effect and the estimate are likely to be close, but there is a 
possibility that they are substantially different. 
Low certainty: Confidence in the effect estimate is limited, the true effect and the estimate may 
be substantially different. 
Very low certainty: There is very little confidence in the findings: the true effect is likely to be 






Full search strategy 
Database/ Resource Strategy 
Embase Healthcare Databases Advanced Search 
(HDAS) 
#1 (cystic fibrosis).ti,ab,if,sh 
#2 (mucoviscidos*).ti,ab,if,sh 
#3 cystic* ADJ10 (fibro*).ti,ab,if,sh 
#4 fibrocyst* ADJ10 (pancrea).ti,ab,if,sh 
#5 "CYSTIC FIBROSIS"/ 
#6 (1 OR 2 OR 3 OR 4 OR 5) 
#7 diabetes OR glucose OR insulin OR sugar OR 
(CFRD).ti,ab,if,sh 
#8 exp "DIABETES MELLITUS"/ 
#9 (7 OR 8) 
#10 (6 AND 9) 
#11 (guide OR guided OR test* OR monitor OR 
monitoring OR manage OR management OR led 
OR CGMS).ti,ab,if 
#12 (10 AND 11) 
#13 "RANDOMIZED CONTROLLED TRIAL"/ 
#14"CONTROLLED CLINICAL TRIAL"/ 
#15 (random*).ti,ab 
#16 RANDOMIZATION/ 
#17 "INTERMETHOD COMPARISON"/ 
#18 (placebo).ti,ab 
#19 compare OR compared OR (comparison).ti 
#20 (evaluated OR evaluate OR evaluating OR 
assessed OR assess) AND (compare OR 
compared OR comparing OR comparison).ab 
#21 open ADJ (label).ti,ab 
#22 (double OR single OR doubly OR singly) ADJ 
(blind OR blinded OR blindly).ti,ab 
#23 "DOUBLE BLIND PROCEDURE"/ 
#24 (parallel group*1).ti,ab 
#25 crossover OR (cross over).ti,ab 
[86] 
 
#26 (assign* OR match OR matched OR 
allocation) ADJ5 (alternate OR group*1 OR 
intervention*1 OR patient*1 OR subject*1 OR 
participant*1).ti,ab 
#27 assigned OR (allocated).ti,ab 
#28 controlled ADJ7 (study OR design OR 
trial).ti,ab 
#29 volunteer OR (volunteers).ti,ab 
#30 "HUMAN EXPERIMENT"/ 
#31 (trial).ti 
#32 (13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 
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#33 ((random* ADJ sampl*) ADJ7 ("cross 
section*" OR questionnaire*1 OR survey* OR 
database*1).ti,ab) NOT ("COMPARATIVE 
STUDY"/ OR "CONTROLLED STUDY"/ OR 
(randomi?ed controlled).ti,ab OR (randomly 
assigned).ti,ab) 
#34 "CROSS-SECTIONAL STUDY"/ NOT 
("RANDOMIZED CONTROLLED TRIAL"/ OR 
"CONTROLLED CLINICAL STUDY"/ OR 
"CONTROLLED STUDY"/ OR (randomi?ed 
controlled).ti,ab OR (control group*1).ti,ab) 
#35 ((case ADJ control*) AND random*) NOT 
(randomi?ed controlled).ti,ab 
#36 Systematic review NOT (trial OR study).ti 
#37 nonrandom* NOT (random*).ti,ab 
#38 ("Random field*").ti,ab 
#39 random cluster ADJ3 (sampl*).ti,ab 
#40 ((review).ab AND (review).pt) NOT (trial).ti 




#42 ("update review").ab 
#43 databases ADJ4 (searched).ab 
#44 (rat OR rats OR mouse OR mice OR swine 
OR porcine OR murine OR sheep OR lambs OR 
pigs OR piglets OR rabbit OR rabbits OR cat OR 
cats OR dog OR dogs OR cattle OR bovine OR 
monkey OR monkeys OR trout OR 
marmoset*1).ti AND "ANIMAL EXPERIMENT"/ 
#45 "ANIMAL EXPERIMENT"/ NOT ("HUMAN 
EXPERIMENT"/ OR "HUMAN"/) 
#46 (33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 
OR 40 OR 41 OR 42 OR 43 OR 44 OR 45) 
#47 32 NOT 46 
#48 (12 AND 47) 
Web of Science Core Collection (Indexes=SCI-
EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, 
BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC ) 
[Advanced Search] 
#1 TS=(cystic fibrosis) 
#2 TS=(mucoviscidos*) 
#3 TS=(cystic* NEAR/10 fibro*) 
#4 TS=(fibrocyst* NEAR/10 pancrea*) 
#5 #4 OR #3 OR #2 OR #1 
#6 TS=(diabetes OR glucose OR insulin OR sugar 
OR CFRD OR CRD**) 
#7 #6 AND #5 
#8 TS=(guide OR guided OR test* OR monitor* 
OR manage OR management OR led OR CGMS 
OR CGM) 
#9 #8 AND #7 
#10 TS=(trial* OR stud* OR control* OR 
random* OR cross* OR factorial* OR blind* OR 
mask* OR dummy OR assign* OR doubl* OR 
singl* OR tripl* OR trebl* OR placebo OR 




#11 #10 AND #9 
 
Clinicaltrials.gov [Advanced Search] 
CONDITION/ DISEASE: Cystic Fibrosis Diabetes 
OR cfrd 
OTHER TERMS: guide OR guided OR test OR 
testing OR monitor* OR manage OR 
management OR CGMS OR led OR adjust OR 
adjusted OR modify OR modified 
STUDY TYPE: Interventional Studies 
Australian New Zealand Clinical Trials Registry 
(ANZCTR) 
[Advanced Search Form] 
REGISTRY: ANZCTR 
HEALTH CONDITION(S) OR PROBLEM(S) 
STUDIED: diabetes 
CONDITION CATEGORY: Human Genetics and 
Inherited Disorders 
CONDITION CODE: cystic fibrosis 
WHO ICTRP [Advanced Search Form] 
 
TITLE: diabetes OR CFRD OR CFD 
and 
CONDITION: cystic fibrosis 












The James Lind Alliance’s cystic fibrosis PSP’s top 10 research priorities (2017) 
 
1. Finding effective ways of simplifying the treatment burden experienced by pwCF. 
 
2. Relieving gastro-intestinal symptoms, such as stomach pain, bloating and nausea in pwCF. 
 
3. Determining the best treatment (including which medication and when this should start) for 
non-tuberculous mycobacterium in pwCF. 
 
4. Identifying which therapies are effective in delaying or preventing the progression of lung 
disease in the early life of pwCF. 
 
5. Ways of preventing the development of CFRD in pwCF. 
 
6. Assessing what technological advancements and effective ways of motivating, supporting pwCF 
can help improve and sustain adherence to their treatment. 
 
7. Evaluating whether exercise could replace chest physiotherapy in the treatment of CF. 
 
8. Establishing which antibiotic combinations and doses should be used during exacerbations in CF, 
and whether these should be rotated. 
 
9. Exploring ways of reducing the negative effects of antibiotics including resistance and adverse 
symptoms in pwCF. 
 
10. Exploring the best way of eradicating Pseudomonas aeruginosa in pwCF. 
